Prof. Stefano Pallanti - CV 18 Agosto 2022

CURRICULUM VITAE
STEFANO PALLANTI, M.D. PhD
H-index: 60 (as of April 2022)
EDUCATION
December 1983
Medical Doctorate Degree (M.D.) and European Medical License, 6-year
course, final dissertation thesis “Life events and Depression”
University of Florence, School of Medicine, Florence, Italy
November 1987
Residency In Psychiatry, 4-year course, final dissertation thesis “Life Events
and Schizophrenia”
November 1988
Residency in NeuroPhysiopathology admitted to the second year.
June 1993 Ph.D in Neurophysiopathology, 4-year course, final dissertation thesis
“Contingent Negative Variation in Normal Elderly Population “
May 2013 Certificate of Deep TMS Operation, completed by Brainsway Inc., Israel
May 2018 Certificate of completion of Electroconvulsive Therapy Training, completed by
Villa Baruzziana, Ospedale privato accreditato Neuropsichiatrco,
Bologna, Italy
MEDICAL LICENSES
Italian Licence to Practice, Registration at the Provincial Association of Doctor-
Surgeons and Dentists in Florence, Italy: Licenced on 30 November 1983, Registered on
23 January 1984, Licence number 7745
General Medical Council (UK) Registration: 18 June 2012, Registration n°7125393
Schweizerische Eidgenossenschaft (Swiss Confederation) Registration: 7 November
2012, Registration n° GNL7601000979667
Medical Board of California, USA: November 13, 2013 - November, 13 2014, Registration
n°F5799, NPI n° 19322939038, DEA Registration number: FP4286628 (2113 Permit)
Medical Board of California, USA: March 29, 2018 - December 12, 2019, Registration
n°SFP000035, NPI n° 19322939038, DEA Registration number: FP4286628 (2168 Permit)

PROFESSIONAL APPOINTMENTS
Present Employment
Since 1989 Founder, Owner, CEO, Administrator, Strategic and Scientific Director,
Istituto di Neuroscienze, Via A. Lamarmora 24, Firenze, Italy, A private
institution for research, diagnosis, rTMS and tDCS therapy in Psychiatry,
Neurology and Clinical Psychology. Accredited by the University of Florence
for Post-Graduate Internship.
Since 2004 Founder, Director and Administrator, Clinical Neurosciences ONLUS, Via
Dè Fossi 12, Firenze, Italy, A non-profit organization that organizes
scientific CME courses in collaboration with the University of Florence (Italy)
Academic Appointments
2001 – 2020 Tenured Professor of Psychiatry University of Florence, School of
Medicine, Florence, Italy
2000 – 2010 Scientific Secretary and Coordinator, Tuscany School of Psychiatry (Three
Tuscan Universities' Consortium: University of Florence, Pisa and Siena)
2004 Board Member and Coordinator, International Affairs Office of the
University of Florence
Since 2004 Member of Board of Directors, International Master in Affective
Neuroscience, University of Maastricht, The Netherlands and University
of Florence, Italy
2004 – 2005 Visiting Associate Professor in Overseas Studies, Stanford Program in
Florence, School of Humanities and Sciences, Stanford University
2004 – 2005 Professor in Emergency Psychiatry, Emergency Medicine Post Doctorate
Master course, Harvard School of Medicine, Massachusetts, U.S. and
University of Florence, Florence, Italy
2006 – 2007 Director and Organizer, Medical School Course of Psychiatry in English,
University of Florence, Italy
2007 – 2008 Director, Strategic Center of Excellence of Psychiatry, Icahn School
of Medicine at Mount Sinai New York, USA
Since 2008 Member of Board of Directors, Dottorato Toscano di Neuroscienze,
2008 - 2010 Director of Master in Mindfulness (“Meditation and Mindfulness:
Neurosciences and Clinical applications in Health Care”) University of
Florence
Since 2010 Director of the Graduate Course on Health Education, University of
Florence, School of Medicine, Florence, Italy

Since 2010 Chair of Education and Director of the Residency Program of Psychiatry,
Since 2012 Italian National Scientific Qualification as a full professor
2013 - 2014 Professor of Psychiatry and Behavioral Sciences, Early Diagnosis and
Preventive Treatment Clinic, Psychosomatic Unit, Responsible for the
Neuromodulation Program, UC Davis, CA, USA
Since 2013 Visiting Professor, Albert Einstein College of Medicine, Montefiore
Medical Center New York, USA
2013 Qualified as a Full Professor, University of Florence
Since 2016 Visiting Professor, Imperial College, London, UK
2017 – 2019 Professor of Psychiatry and Behavioral Sciences (General Psychiatry and
Psychology (Adult), Stanford University, Stanford, CA, USA
Since 2018 Faculty, Università di Pisa, Dipartimento di Medicina Clinica e
Sperimentale
Since 2019 Faculty, The European Network for Problematic Usage of the Internet,
Training School at Clare College, Cambridge University
Since 2019 Faculty, International Psychopharmacology Course, Harvard University and
Massachusetts General Hospital Psychiatry Academy
Since 2022 Honarary Professor, Instituto Universitario de Neurociencias, Universidad de
La Laguna, San Cristóbal de La Laguna, Spagna
Clinical Activities
1984 –1988 Chief Residency in Psychiatry
1988 –1990 Residency in Neurology
1990 –1993 Residency in Clinical Neurophysiology
Since 1989 Clinical Director, Istituto di Neuroscienze, Italy
2000 – 2020 Dirigente Medico 1st level (Medical Director), Psychiatric Clinic, Azienda
Ospedaliero Universitaria Careggi (University of Florence Hospital),
Department of Neuropharba
2000 – 2020 Director of the OCD Spectrum Disorders programme, Psychiatric Clinic,
Azienda Ospedaliero Universitaria Careggi, University of Florence Hospital,
Department of Neuropharba
2009 - 2014 Director of Psychosomatic and Liaison psychiatry, Azienda Ospedaliera
Universitaria Careggi, University of Florence, Florence, Italy

2013 - 2014 Clinical Practice, Sacramento EDAPT and EDAP programs (Early Diagnosis
and Preventing Treatment of Psychosis Illness), Liaison Psychiatry Consultant, UC
Davis Medical Hospital, CA, USA
2018 - 2019 Professor of Psychiatry and Behavioural Sciences, Stanford University, CA,
USA
Professional Memberships and Services
Since 1994 International Advisory Board member, American Psychiatric Association
(APA) for DSM V and DSM 5.0 TR
Since 1999 Member of the Steering Committee, International OCD Consortium
Since 2000 Member of Board of Directors, International Master in Affective
Neuroscience, Universities of Maastricht and Florence
Since 2004 Board member, International College of Obsessive-Compulsive
Spectrum Disorders (ICOCS), UK
Since 2004 Scientific Advisory Panel Member for Anxiety and Anxiolytics session,
European College of Neuropsychopharmacology (ECNP)
Since 2005 Member of International Advisory Board, American Psychiatric
Association (APA) for DSM 5.0 (Chair D.J. Kupfer)
2005 - 2007 Member of the OCD spectrum workgroup Impulse Control Disorders
Taskforce and International Advisory Board, American Psychiatric
Association (APA) for DSM 5.0 (Chair D.J. Kupfer)
Since 2009 Member of the Advisory Council, icare4autism (International Center for
Autism Research and Education), New York, USA
2011 –2014 Member of the European College of Neuropsychopharmacology
Educational Committee
Since 2011 Member of the ECNP Obsessive Compulsive and Related Disorders
Network
Since 2013 Fellow, European College of Neuropsychopharmacology
Since 2013 Member of the New York Psychiatric Society, NY, USA
2013 – 2017 Member of the Board of Directors, Clinical TMS Society, Greenwich, CT,
USA
Since 2014 World Health Organization expert in Anxiety
Since 2014 International Fellow, American Psychiatric Association (APA)
Since 2015 Member of the Board, (anxiety section) World Psychiatric Association

2016 - 2019 Executive Committee Member, European College of
Neuropsychopharmacology
Since 2017 Ambassador, European College of Neuropsychopharmacology
Since 2017 Member of the PANDAS Physicians Network
Since 2018 Board member, European Research Area Networks NEURON (ERA-NET
NEURON)
Since 2019 Chair, Neuromodulation Network, European College of
Neuropsychopharmacology
Since 2020 International Expert, German Association of Scientific Medical As
sociations on behalf of the German Society for Child and Adolescent
Psychiatry, Psychosomatics and Psychotherapy (DGKJPP) for develop-
ment of the interdisciplinary evidence- and consensus-based S3-Guideline
for the diagnosis and treatment of obsessive-compulsive disorder in child-
hood and adolescence (interdisziplinäre evidenz- und konsensbasierte S3-
Leitlinie für Diagnostik und Therapie von Zwangsstörungen im Kindes- und
Jugendalter)
Since 2020 Member of the International Neuroethics Society
Since 2020 Board member, The European Commission consensus initiative on
depression and its treatment (EU PEARL)
Since 2021 Member, WHO - World Health Organization funded COVID-19 Clinical Re-
search Coalition’s Ethics Working Group, the Good Clinical Practice Al-
liance – Europe (GCPA)
Service as a member of Grant Review Committee
2011 Member of Research Funding Evaluation Committee, UK General Medical
Research Council
Since 2011 Member of the Board of Research Funding Evaluation Committee
SAMENTA, Agence Nationale dela Recherche, Paris, France
2013 Member of the Expert Review Board, The ERA-NET scheme of the
European Commission 'Network of European Funding for Neuroscience
Research' (NEURON) for its funding initiative "European Research Projects
on Mental Disorders"
Since 2018 Member of the Spark Evaluation Committee, the Swiss National Science
Foundation (SNSF)
2020 Specialist Evaluating Committee Member, National Research Foundation
(NRF), South Africa
2020 Board of Reviewers, Catalan biomedical research funding programme "La
Marató de TV3", Agency for Health Quality and Assessment of Catalonia,
Spain

Professional Honors and Awards
October 2004 ECNP poster-travel award
February 2005 Società Italiana di Psicopatologia (SOPSI) poster research award
May 2007 CNS Spectrum 2007 Breakthrough Paper Award
TEACHING
Master Training Class in Neuromodulation, European College of
Neuropsychopharmacology (ECNP)
Since 2020 Organizer and speaker for ECNP Network, Thematic Working Group
University of Florence, Italy
1993 - 2019 Psychopathology Course (Course Director and Lecturer)
1993 – 2019 Psychopathology in the Residency Programme (Course Director and
Lecturer)
2000 – 2019 Undergraduate Psychiatry Course (Course Director and Lecturer)
2001 – 2019 Medical Thesis Advisor
2006 - 2007 English language Medical School Course of Psychiatry (Director)
2007 – 2019 Suicide Prevention Course for Medical students, Nurse and Social
Workers (Director)
2010 – 2019 Psychopharmacology Course (Course Director and Lecturer)
2012 – 2012 Master's Program in Mindfulness (Director)
2016 - 2017 Neurocircuitry Research Domain Criteria and Precision Psychiatry
Course (Course Director and Lecturer)
2010 - Present Post-Graduate Psychiatry Course (Course Director and Lecturer)
Weekend Educative Course in Psychiatry, India
2017 – 2018 Elite faculty for enforcement program of neuropsychiatry in India
University of Maastricht and University of Florence,
1995 - Present International Master Degree in Affective Neuroscience (joint program) -
course design, material development, lectures, and thesis advising

Continuing Medical Education (CME) European Accreditation Council for CME
2009 - 2013 Managing Anxiety in Practice CME Course design, course material
development (Slides, Booklet and CD-ROM) and lectures. Total of 6
courses held in Berlin (Germany), London (UK), Athens (Greece), Rome
(Italy), Munich (Germany) and Paris (France)
Florence Summer Course – Organizer, Scientific Director, Chair and Speaker
2004 7 - 14 Aug. Anxiety and Impulsivity
2005 30 July - 1 Aug. Neuroscience of Affective Disorder Spectrum
2006 14 -15 Sept. Psychiatric Disorder and Day Hospital
2007 31 Ago. - 3 Sept. Anxiety Disorders and Psychosis
2008 4 - 6 Sept. Aspect of Contemporary Psychiatric Disorders
2009 5 - 7 Sept. A Lesson on Great American Studies on Efficiency and
Personalized Therapies in Psychiatry
2010 3 - 5 Sept. Aspect of Contemporary Psychiatry
2011 9 - 11 Sept. Toward and Individualized Therapy – Evolution of Psychiatry,
from Disorder to “Research Domain”
2012 19 - 21 Oct. Quality in Clinical Psychiatry
2013 11 - 12 Oct. Clinical Staging and Pathophysiology of Brain Desease
2014 23 - 24 Oct. Total Resources: Look after Brain Disorders and Take Care of
Mental Suffering
Coordinator, Interuniversity cooperation agreements
Since 2004 Board member of the International Affairs Office of the University of Florence,
On-going International educational collaborative programmes between Univ. of Florence
and:
Columbia University (USA) in 2010
University of Balamand (Lebanon) in 2009
Mount Sinai School of Medicine (USA) in 2004
Stanford University (USA) in 2004
SCHOLARSHIP
Peer-Reviewed Original Research Publications (extracts)
1. Faravelli C, Sacchetti E, Ambonetti A, Conte G, Pallanti S, Vita A. Recent life events
and affective disorder revisited. British Journal of Psychiatry. 1986 Mar;148:288-95.

2. Faravelli C, Ambonetti A, Pallanti S, Pazzagli A. Depressive relapses and incomplete
recovery from index episode. American Journal of Psychiatry. 1986 Jul;143(7):888-
91.
3. Faravelli C, Pallanti S. Clomipramine by different routes of administration: short- and
long-term efficacy and predictors of clinical outcome. Psychopharmacol Bull.
1987;23(3):459-63.
4. Faravelli C, Pallanti S, Frassine R, Albanesi G, Guerrini Degl'Innocenti B. Panic
attacks with and without agoraphobia: a comparison. Psychopathology.
1988;21(1):51-6.
5. Faravelli C, Pallanti S, Strik WK. [Stress load and schizophrenic disorder].
Nervenarzt. 1988 Apr;59(4):237-9. German.
6. Faravelli C, Pallanti S. Recent life events and panic disorder. American Journal of
Psychiatry. 1989 May;146(5):622-6.
7. Smeraldi E, Orsini A, Gasperini M, Sciuto G, Battaglia M, Cassano GB, Perugi G,
Faravelli C, Pallanti S, Bressa G. Familial analysis of panic disorder and
agoraphobia. Journal of Affective Disorders, 1989, vol.17, p.1-8. ISSN: 0165-0327.
8. Faravelli C, Guerrini Degl'Innocenti B, Aiazzi L, Incerpi G, Pallanti S. Epidemiology
of mood disorders: a community survey in Florence. Journal of Affective Disorders.
1990 Oct;20(2):135-41.
9. Faravelli C, Panichi C, Pallanti S, Paterniti S, Grecu LM, Rivelli S. Perception of
early parenting in panic and agoraphobia. Acta Psychiatrica Scandinavica. 1991
Jul;84(1):6-8.
10. Faravelli C, Pallanti S, Biondi F, Paterniti S, Scarpato MA. Onset of panic disorder.
American Journal of Psychiatry. 1992 Jun;149(6):827-8.
11. Pallanti S, Mazzi D. MDMA (Ecstasy) precipitation of panic disorder. Biological
Psychiatry. 1992 Jul 1;32(1):91-5.
12. Zaccara G, Gangemi PF, Muscas GC, Paganini M, Pallanti S, Parigi A, Messori A,
Arnetoli G. Smooth-pursuit eye movements: alterations in Alzheimer's disease.
Journal of the Neurological Science. 1992 Oct;112(1-2):81-9. Volume 112, Issues 1–
2, 1992,
13. Pages 81-89. ISSN 0022-510X. https://doi.org/10.1016/0022-510X(92)90136-9.
a. (https://www.sciencedirect.com/science/article/pii/0022510X92901369)
14. M.Weissman, L.Bobins, J.Escobar, R.Bland, G.Canino, H.Wittchen, C.Faravelli,
S.Pallanti, J.Lepine, P.Pariente, E.Karam, J.Wells, H.Hwu, G.Klerman, P.Lavori,
W.Maier (1992). The changing rate of depression. JAMA, vol. 268, p. 3098-3105,
ISSN: 0098-7484.
15. Pallanti S., Pavia R.S. A demencia emu ma prospectiva psico (pato) lògica.
[Dementia in a psycho(patho)logical perspective] Jornal Brasiliero de Psiquiatria
[Brazilian Journal of Psychiatry] 41 (9), 447-50. Ott. 1992.

16. Faravelli C., Pallanti S., Biondi F., Paterniti S., Scarpato M.A. Assessment of onset
of panic disorder in relatrion to onset of agoraphobia-replay. American Journal of
Psychiatry 150 (9), 1437-1437. 1993-09-01.
17. Pallanti, S. et al. Depth perception in schizophrenia. Biological Psychiatry, Volume
35, Issue 9, 637 – 638 Published in issue: May 01, 1994
18. Mortilla M, Amaducci L, Bruni A, Montesi MP, Trubnikov A, De Cataldo S, Pallanti S,
Pazzagli A, Grecu L, Servi P, et al. Absence of APP713 mutation in Italian and
Russian families with schizophrenia. Neuroscience Letters 1994 Jan 3;165(1-2):45-
7.
19. Grassi E, Mortilla M, Amaducci L, Pallanti S, Pazzagli A, Galassi F, Guarnieri
BM, Petruzzi C, Bolino F, Ortenzi L, Nistico R, De Cataldo S, Rossi A, Sorbi S. No
evidence of linkage between schizophrenia and D2 dopamine receptor gene locus in
Italian pedigrees. Neuroscience Letters 1996 Mar 15;206(2-3):196-8.
20. Pallanti S, Grecu LM, Gangemi PF, Massi S, Parigi A, Arnetoli G, Quercioli L,
Zaccara G. Smooth-pursuit eye movement and saccadic intrusions in obsessive-
compulsive disorder. Biological Psychiatry. 1996 Dec 1;40(11):1164-72.
21. Pallanti S, Koran LM. Two case report. CNS Spectrums 1996, vol.1, p.54-57,
ISSN: 1092-8529.
22. Bersani G., Saito A. Pallanti S. Sasso E., Tosca P. Clinical variables and
response to citalopram in Major Depression: an open multicentric study. Rivista di
Psichiatria 32, 260-267, 1997.
23. Pallanti S. Personality Disorders: Myths and Neuroscience. CNS Spectrums
2, 53-63, 1997.
24. Koran LM, Sallee FR, Pallanti S. Rapid benefit of intravenous pulse loading of
clomipramine in obsessive-compulsive disorder. American Journal of Psychiatry.
1997 Mar;154(3):396-401.
25. Pallanti S, Quercioli L, Pazzagli A. Relapse in young paranoid schizophrenic
patients: a prospective study of stressful life events, P300 measures, and coping.
American Journal of Psychiatry. 1997 Jun;154(6):792-8.
26. Ramacciotti A, Pallanti S, Pazzagli A. A setting including psychotherapy and
psychopharmacological treatment in a case of anorexia nervosa with obsessive
compulsive disorder comorbidity. Eating and Weight Disorders. 1997 Dec;2(4):222-
8.
27. Inzitari D, Pantoni L, Lamassa M, Pallanti S, Pracucci G, Marini P. Emotional
arousal and phobia in transient global amnesia. Archives of Neurology. 1997
Jul;54(7):866-73.
28. Pallanti S, Quercioli L, Ramacciotti A. Citalopram in anorexia nervosa. Eating and
Weight Disorders. 1997 Dec;2(4):216-21.

29. Pallanti S, Quercioli L, Zaccara G, Ramacciotti AB, Arnetoli G. Eye movement
abnormalities in anorexia nervosa. Psychiatry Research. 1998 Mar 20;78(1-2):59-70.
30. Koran LM, Pallanti S, Paiva RS, Quercioli L. Pulse loading versus gradual dosing of
intravenous clomipramine in obsessive-compulsive disorder. Eur
Neuropsychopharmacol. 1998 May;8(2):121-6.
31. Sallee FR, Koran LM, Pallanti S, Carson SW, Sethuraman G. Intravenous
clomipramine challenge in obsessive-compulsive disorder: predicting response to
oral therapy at eight weeks. Biological Psychiatry. 1998 Aug 1;44(3):220-7.
32. Pallanti, S., Quercioli, L. Cognitive subjective disturbances of schizophrenia: Effect
of atypical neuroleptics. European Neuropsychopharmacology, 1999
33. Pallanti S., Quercioli L. Objective and subjective investigation of cognitive deficits in
young schizophrenic patients. Journal of Psychophysiology 13 (3), 203-203, 1999-
01-01.
34. Pallanti S, Koran LM. Citalopram and sexual side effects of selective serotonin
reuptake inhibitors. American Journal of Psychiatry. 1999 May;156(5):796.
10327919.
35. Pallanti S, Quercioli L, Pazzagli A. Effects of clozapine on awareness of illness and
cognition in schizophrenia. Psychiatry Research. 1999 Jun 30;86(3):239-49.
36. Pallanti S, Quercioli L, Pazzagli A, Rossi A, Dell'Osso L, Pini S, Cassano GB.
Awareness of illness and subjective experience of cognitive complaints in patients
with bipolar I and bipolar II disorder. American Journal of Psychiatry. 1999
Jul;156(7):1094-6.
37. Pallanti S, Quercioli L, Paiva RS, Koran LM. Citalopram for treatment-resistant
obsessive-compulsive disorder. European Psychiatry. 1999 Apr;14(2):101-6.
38. Pallanti S, Quercioli L, Pazzagli A. Basic symptoms and P300 abnormalities
in young schizophrenic patients. Comprehensive Psychiatry. 1999 Sep-
Oct;40(5):363-71.
39. Pini S, Dell'Osso L, Mastrocinque C, Marcacci G, Papasogli A, Vignoli S,
Pallanti S, Cassano G. Axis I comorbidity in bipolar disorder with psychotic features.
British Journal of Psychiatry 1999.467-71.
40. Pallanti S, Quercioli L, Rossi A, Pazzagli A. The emergence of social phobia
during clozapine treatment and its response to fluoxetine augmentation. Journal of
Clinical Psychiatry. 1999 Dec;60(12):819-23.
41. Di Russo F, Zaccara G, Ragazzoni A, Pallanti S. Abnormal visual event-
related potentials in obsessive-compulsive disorder without panic disorder or
depression comorbidity. Journal of Psychiatric Research. 2000 Jan-Feb;34(1):75-82.
42. Pallanti S, Quercioli L. Shame and psychopathology. CNS Spectrums. 2000
Aug;5(8):28-43.

43. Pallanti S, Quercioli L, Pazzagli A. Social anxiety and premorbid personality
disorders in paranoid schizophrenic patients treated with clozapine. CNS Spectrums.
2000 Sep;5(9):29-43.
44. Rossi A, Arduini L, Stratta P, Pallanti S. Subjective experience and subjective
response to neuroleptics in schizophrenia. Comprehensive Psychiatry. 2000 Nov-
Dec;41(6):446-9.
45. Koran LM, Pallanti S, Quercioli L. Sumatriptan, 5-HT(1D) receptors and
obsessive-compulsive disorder. European Neuropsychopharmacology. 2001
Apr;11(2):169-72.
46. Hollander E., Bienstock C.A., Koran L.M., Pallanti S., Marazzini D.,
Rasmussen S.A., Ravizza L., Benkelfat C., saxena S., Greenberg D.B., Sasson Y.,
Zohar J. Refractory obsessive-compulsive disorder: state-of-the-art treatment.
Journal of Clinical Psychiatry 63, 20-29, 12-2001.
47. Pallanti S., Quercioli L. Alternative route of administration and titration of SRIs
in anxious resistant patients:Two day-hospital experiences. European
Neuropsychopharmacology 11, S312, 2001-12-31.
48. Ramacciotti A, Sorbello M, Pazzagli A, Vismara L, Mancone A, Pallanti S.
Attachment processes in eating disorders. Eat Weight Disord. 2001 Sep;6(3):166-70.
49. Presta S, Marazziti D, Dell'Osso L, Pfanner C, Pallanti S, Cassano GB.
Kleptomania: clinical features and comorbidity in an Italian sample. Comprehensive
Psychiatry. 2002 Jan-Feb;43(1):7-12.
50. Hollander E, Bienstock CA, Koran LM, Pallanti S, Marazziti D, Rasmussen
SA, Ravizza L, Benkelfat C, Saxena S, Greenberg BD, Sasson Y, Zohar J. Refractory
obsessive-compulsive disorder: state-of-the-art treatment. Journal of Clinical
Psychiatry. 2002;63 Suppl 6:20-9.
51. Pallanti S, Hollander E, Bienstock C, Koran L, Leckman J, Marazziti D, Pato
M, Stein D, Zohar J; International Treatment Refractory OCD Consortium. Treatment
non-response in OCD: methodological issues and operational definitions.
International Journal of Neuropsychopharmacology. 2002 Jun;5(2):181-91.
52. Pallanti S, Quercioli L, Sood E, Hollander E. Lithium and valproate treatment
of pathological gambling: a randomized single-blind study. Journal of Clinical
Psychiatry. 2002 Jul;63(7):559-64.
53. Pallanti S, Quercioli L, Koran LM. Citalopram intravenous infusion in resistant
obsessive-compulsive disorder: an open trial. Journal of Clinical Psychiatry. 2002
Sep;63(9):796-801.
54. Pallanti S, Baldini Rossi N, Sood E, Hollander E. Nefazodone treatment of
pathological gambling: a prospective open-label controlled trial. Journal of Clinical
Psychiatry. 2002 Nov;63(11):1034-9.

55. Buchsbaum M.S., Hollander E., Pallanti S., Baldini-Rossi N. Brikman A.M.,
Platholi J., Sood E. Positron emission tomography. Imaging of risperidone
augmentation in SRI-refractory patients. Biological Psychiatry 51 (8), 47S-47S, 2002-
04-14.
56. Pallanti S., Rossi N.B., Friedberg J., Hollander E. Psychobiology of Impulse-
Control Disorders Not Otherwise Specified (NOS). Biological Psychiatry 2003, 1315-
1329.
57. Sood ED, Pallanti S, Hollander E. Diagnosis and treatment of pathologic
gambling. Current Psychiatry Reports. 2003 May;5(1):9-15.
58. Hollander E, Baldini Rossi N, Sood E, Pallanti S. Risperidone augmentation
in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-
controlled study. International Journal of Neuropsychopharmacology. 2003
Dec;6(4):397-401.
59. Pallanti S, Quercioli L, Hollander E. Social anxiety in outpatients with
schizophrenia: a relevant cause of disability. American Journal of Psychiatry. 2004
Jan;161(1):53-8.
60. Pallanti S, Quercioli L, Bruscoli M. Response acceleration with mirtazapine
augmentation of citalopram in obsessive-compulsive disorder patients without
comorbid depression: a pilot study. Journal of Clinical Psychiatry. 2004
Oct;65(10):1394-9.
61. Pallanti S, Hollander E, Goodman WK. A qualitative analysis of nonresponse:
management of treatment-refractory obsessive-compulsive disorder. Journal of
Clinical Psychiatry. 2004;65 Suppl 14:6-10.
62. Hollander E, Pallanti S, Allen A, Sood E, Baldini Rossi N. Does sustained-
release lithium reduce impulsive gambling and affective instability versus placebo in
pathological gamblers with bipolar spectrum disorders? American Journal of
Psychiatry. 2005 Jan;162(1):137-45.
63. Hollander E, Sood E, Pallanti S, Baldini-Rossi N, Baker B. Pharmacological
treatments of pathological gambling. Journal of Gambling Studies. 2005
Spring;21(1):99-110.
64. Haznedar MM, Roversi F, Pallanti S, Baldini-Rossi N, Schnur DB, Licalzi EM, Tang
C, Hof PR, Hollander E, Buchsbaum MS. Fronto-thalamo-striatal gray and white
matter volumes and anisotropy of their connections in bipolar spectrum illnesses.
Biological Psychiatry. 2005 Apr 1;57(7):733-42.
65. Urpe M, Pallanti S, Lotti T. Psychosomatic factors in dermatology. Dermatologic
Clinics. 2005 Oct;23(4):601-8.
66. Pallanti S, Lotti T, Urpe M. Psychoneuroimmunodermatology of atopic dermatitis:
from empiric data to the evolutionary hypothesis. Dermatologic Clinics. 2005
Oct;23(4):695-701.

67. Hollander E, Pallanti S, Baldini Rossi N, Sood E, Baker BR, Buchsbaum MS. Imaging
monetary reward in pathological gamblers. World Journal of Biological Psychiatry.
2005;6(2):113-20.
68. Pallanti S, Lassi S, La Malfa G, Campigli M, Di Rubbo R, Paolini G, Cesarali V. Short
report: Autistic gastrointestinal and eating symptoms treated with secretin: a subtype
of autism. Clinical Practice & Epidemiology in Mental Health. 2005 Nov 15; 1:24.
69. Pallanti S, DeCaria CM, Grant JE, Urpe M, Hollander E. Reliability, and validity of
the pathological gambling adaptation of the Yale-Brown Obsessive-Compulsive Scale
(PG-YBOCS). Journal of Gambling Studies. 2005 Winter;21(4):431-43.
70. Rossi A, Rucci P, Mauri M, Maina G, Pieraccini F, Pallanti S, Endicott J; (For the
EQUIP group). Reliability and validity of the Italian version of the Quality of Life,
Enjoyment and Satisfaction Questionnaire. Quality of Life Research. 2005
Dec;14(10):2323-8.
71. Pallanti S, Quercioli L. Treatment-refractory obsessive-compulsive disorder:
methodological issues, operational definitions and therapeutic lines. Progress in
Neuro-Psychopharmacology & Biological Psychiatry. 2006 May;30(3):400-12.
72. Pallanti, S. (2006). From Impulse-Control Disorders Toward Behavioral Addictions.
CNS Spectrums. 11. 921-922. 10.1017/S1092852900015108.
73. Buchsbaum MS, Hollander E, Pallanti S, Baldini Rossi N, Platholi J, Newmark R,
Bloom R, Sood E. Positron emission tomography imaging of risperidone
augmentation in serotonin reuptake inhibitor-refractory patients.
Neuropsychobiology. 2006;53(3):157-68.
74. Pallanti S, Bernardi S, Quercioli L, DeCaria C, Hollander E. Serotonin dysfunction in
pathological gamblers: increased prolactin response to oral m-CPP versus placebo.
CNS Spectrums. 2006 Dec;11(12):956-64.
75. Pallanti S, Bernardi S, Quercioli L. The Shorter PROMIS Questionnaire and the
Internet Addiction Scale in the assessment of multiple addictions in a high-school
population: prevalence and related disability. CNS Spectrums. 2006;11(12):966-74.
76. Pallanti S, Quercioli L. Resistant social anxiety disorder response to Escitalopram.
Clinical Practice & Epidemiology in Mental Health. 2006;13; 2:35.
77. Hollander E, Kim S, Khanna S, Pallanti S. Obsessive-compulsive disorder and
obsessive-compulsive spectrum disorders: diagnostic and dimensional issues. CNS
Spectrums. 2007 Feb;12(2 Suppl 3):5-13.
78. Fineberg NA, Pampaloni I, Pallanti S, Ipser J, Stein DJ. Sustained response versus
relapse: the pharmacotherapeutic goal for obsessive-compulsive disorder.
International Clinical Psychopharmacology 2007;22(6):313-22.
79. Pallanti S, Sandner C. Treatment of depression with selective serotonin inhibitors:
the role of fluvoxamine. International Journal of Psychiatry in Clinical Practice. 2007;
11(3): 233-238.

80. Pallanti S. Transcultural observations of obsessive-compulsive disorder. American
Journal of Psychiatry. 2008 Feb;165(2):169-70.
81. Pallanti S, Masetti S, Bernardi S, Innocenti A, Markella M, Hollander E. Obsessive
compulsive disorder comorbidity in DBA. Clinical Practice & Epidemiology in Mental
Health. 2008 Mar 10; 4:6.
82. La Malfa G, Lassi S, Bertelli M, Pallanti S, Albertini G. Detecting attention-
deficit/hyperactivity disorder (ADHD) in adults with intellectual disability the use of
Conners' Adult ADHD Rating Scales (CAARS). Research in Developmental
Disabilities. 2008 Mar-Apr;29(2):158-64.
83. Pallanti S. Brain plasticity and brain stimulation in neuropsychiatry: toward
individualized medicine. CNS Spectrums. 2008 Apr;13(4):287-92.
84. Hollander E, Buchsbaum MS, Haznedar MM, Berenguer J, Berlin HA, Chaplin W,
Goodman CR, LiCalzi EM, Newmark R, Pallanti S. FDG-PET study in pathological
gamblers. 1. Lithium increases orbitofrontal, dorsolateral, and cingulated metabolism.
Neuropsychobiology. 2008;58(1):37-47.
85. Pallanti S, Hollander E. Obsessive-compulsive disorder spectrum as a scientific
"metaphor". CNS Spectrums. 2008 Sep;13(9 Suppl 14):6-15.
86. Berlin H.A., Koran L.M., Jenike M.A., Shapira N.A., Chaplin W., Pallanti S.,
Hollander E. Double-blind, placebo-controlled trial of topiramate augmentation in the
treatment of obsessive-compulsive disorder. Biological Psychiatry 63 (7), 170S-170S,
2008-04-01.
87. Pallanti S, Bernardi S. Neurobiology of repeated transcranial magnetic stimulation
in the treatment of anxiety: a critical review. International Clinical
Psychopharmacology 2009 Jul;24(4):163-73.
88. Faravelli C, Lo Sauro C, Castellini G, Ricca V, Pallanti S. Prevalence, and correlates
of mental disorders in a school-survey sample. Clinical Practice & Epidemiology in
Mental Health 2009 Nov 24; 5:1-8.
89. Pallanti S, Castellini G, Chamberlain SR, Quercioli L, Zaccara G, Fineberg NA.
Cognitive event-related potentials differentiate schizophrenia with obsessive-
compulsive disorder (schizo-OCD) from OCD and schizophrenia without OC
symptoms. Psychiatry Research. 2009 Nov 30;170(1):52-60.
90. Potenza MN, Koran LM, Pallanti S. The relationship between impulse-control
disorders and obsessive-compulsive disorder: a current understanding and future
research directions. Psychiatry Research. 2009 Nov 30;170(1):22-31.
91. Bernardi S, Pallanti S. Internet addiction: a descriptive clinical study focusing on
comorbidities and dissociative symptoms. Comprehensive Psychiatry. 2009 Nov-
Dec;50(6):510-6.
92. Pallanti S, Bernardi S, Antonini S, Singh N, Hollander E. Ondansetron augmentation
in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind,
prospective study. CNS Drugs. 2009 Dec;23(12):1047-55.

93. Lisanby SH, Pallanti S, Schlaepfer TE. FDA considers classification of ECT. CNS
Spectrums. 2009 Dec;14(12):668-70.
94. Pallanti S, Bernardi S, Di Rollo A, Antonini S, Quercioli L. Unilateral low frequency
versus sequential bilateral repetitive transcranial magnetic stimulation: is simpler
better for treatment of resistant depression? Neuroscience. 2010;5;167(2):323-8.
95. Pallanti S, Bernardi S, Raglione LM, Marini P, Ammannati F, Sorbi S, Ramat S.
Complex repetitive behavior: punding after bilateral subthalamic nucleus stimulation
in Parkinson's disease. Parkinsonism and Related Disorder. 2010 Jul;16(6):376-80.
96. Cecchelli C, Grassi G, Pallanti S. Aripiprazole Improves Depressive Symptoms, and
Immunological Response to Antiretroviral Therapy in an HIV-Infected Subject with
Resistant Depression. Case Reports in Medicine. 2010; 2010:836214.
97. Schlaepfer TE, Lisanby SH, Pallanti S. Separating hope from hype: some ethical
implications of the development of deep brain stimulation in psychiatric research and
treatment. CNS Spectrums. 2010 May;15(5):285-7.
98. Pallanti S., Schlaepfer T.E., Lisanby S.H. The Clinical Future of Repetitive
Transcranical Magnetic Stimulation and Depression: Separating Hope From Hype.
CNS Spectrums 15 (9), 554-557, 2010.
99. Pallanti S, Haznedar MM, Hollander E, Licalzi EM, Bernardi S, Newmark R,
Buchsbaum MS. Basal Ganglia activity in pathological gambling: a
fluorodeoxyglucose-positron emission tomography study. Neuropsychobiology.
2010;62(2):132-8.
100. Pallanti S. Problematic Internet use: is it more compulsory than rewarding or mood
driven? World Psychiatry. 2010 Jun;9(2):96-7.
101. Bernardi S, Cortese S, Solanto M, Hollander E, Pallanti S. Bipolar disorder and
comorbid attention deficit hyperactivity disorder. A distinct clinical phenotype? Clinical
characteristics and temperamental traits. World Journal of Biological Psychiatry. 2010
Jun;11(4):656-66.
102. Pallanti S, Bernardi S, Allen A, Chaplin W, Watner D, DeCaria CM, Hollander E.
Noradrenergic function in pathological gambling: blunted growth hormone response
to clonidine. Journal of Psychopharmacology. 2010 Jun;24(6):847-53.
103. Bernardi S, Pallanti S. Successful duloxetine treatment of a binge eating disorder: a
case report. Journal of Psychopharmacology. 2010 Aug;24(8):1269-72.
104. Pallanti S, Borgheresi A, Pampaloni I, Giovannelli F, Bernardi S, Cantisani A, Zaccara
G, Cincotta M. Motor cortex excitability correlates with novelty seeking in social
anxiety: a transcranial magnetic stimulation investigation. Journal of Neurology. 2010
Aug;257(8):1362-8.
105. Kooij SJ, Bejerot S, Blackwell A, Caci H, Casas-BruguÃ M, Carpentier PJ, Edvinsson
D, Fayyad J, Foeken K, Fitzgerald M, Gaillac V, Ginsberg Y, Henry C, Krause J,
Lensing MB, Manor I, Niederhofer H, Nunes-Filipe C, Ohlmeier MD, Oswald P,

Pallanti S, Pehlivanidis A, Ramos-Quiroga JA, Rastam M, Ryffel-Rawak D, Stes S,
Asherson P. European consensus statement on diagnosis and treatment of adult
ADHD: The European Network Adult ADHD. BMC Psychiatry. 2010;3; 10:67.
106. Pallanti S. Augmentation strategies in resistant obsessive-compulsive disorders
(OCD), International Journal of Psychiatry in Clinical Practice 14, 15-16, 2010-11-01.
107. Pallanti S, Bernardi S, Allen A, Hollander E. Serotonin function in pathological
gambling: blunted growth hormone response to sumatriptan. Journal of
Psychopharmacology. 2010 Dec;24(12):1802-9.
108. Pallanti S. Unique contributions of brain stimulation to the study of consciousness:
where neuroscience meets philosophy. CNS Spectrums. 2010 Mar;15(3):154-6.
109. Berlin HA, Koran LM, Jenike MA, Shapira NA, Chaplin W, Pallanti S, Hollander E.
Double-blind, placebo-controlled trial of topiramate augmentation in treatment-
resistant obsessive-compulsive disorder. Journal of Clinical Psychiatry. 2011
May;72(5):716-21. *Participated extensively in conception and trial design,
participated in drafting, reviewing and critical revision of the manuscript
110. Di Rollo A, Pallanti S. Phantom limb pain: low frequency repetitive transcranial
magnetic stimulation in unaffected hemisphere. Case Reports in Medicine. 2011;
2011:130751.
111. Bernardi S, Faraone SV, Cortese S, Kerridge BT, Pallanti S, Wang S, Blanco C. The
lifetime impact of attention deficit hyperactivity disorder: results from the National
Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Psychological
Medicine. 2011 Aug 16:1-13. *Provided study ideas and concept, participated in the
drafting and revision of the manuscript, and provided mentorship to first author
112. Pallanti S, Grassi G, Sarrecchia ED, Cantisani A, Pellegrini M. Obsessive-
compulsive disorder comorbidity: clinical assessment and therapeutic implications.
Front Psychiatry. 2011; 2:70.
113. Valenti R, Pescini F, Antonini S, Castellini G, Poggesi A, Bianchi S, Inzitari D, Pallanti
S, Pantoni L. Major depression and bipolar disorders in CADASIL: a study using the
DSM-IV semi-structured interview. Acta Neurologica Scandinavica. 2011
Dec;124(6):390-5. *Participated extensively in conception and trial design,
acquisition, analysis and interpretation of data, participated in drafting, reviewing and
critical revision of the manuscript.
114. Baldwin DS, Allgulander C, Bandelow B, Ferre F, Pallanti S. An international survey
of reported prescribing practice in the treatment of patients with generalised anxiety
disorder. World Journal of Biological Psychiatry. 2012; 13(7):510-6.
115. Pallanti, S., Grassi, G. and Cantisani, A. (2012). Approaches to Treatment
Resistance. In Obsessive-Compulsive Disorder, J. Zohar (Ed.)
https://doi.org/10.1002/9781119941125.ch5
116. Moretti S, Arunachalam M, Colucci R, Pallanti S, Kline JA, Berti S, Lotti F, Lotti T.
Autoimmune markers in vitiligo patients appear correlated with obsession and
phobia. Journal of the European Academy of Dermatology and Venereology. 2012;

26(7):861-7. *Participated extensively in conception and trial design, participated in
drafting, reviewing and critical revision of the manuscript
117. Pallanti S, Cantisani A, Grassi G, Antonini S, Cecchelli C, Burian J, Cauli G, Quercioli
L. rTMS age-dependent response in treatment resistant depressed subjects: a mini-
review, CNS Spectrums (2012), 17, 24-30.
118. S. Pallanti, A. Di Rollo, S. Antonini, E. Hollander and L.Quercioli Low Frequency
rTMS over Right Dorsolateral Prefrontal Cortex in the Treatment of Resistant
Depression: Cognitive Improvement is Independent from Clinical Response,
Neuropsychobiology 2012 Jun; 65(4):227-35.
119. Moretti S., Arunachalam M., Colucci R., Pallanti S., Kline JA., Berti S., Lotti F., Lotti
T. Autoimmune markers in vitiligo patients appear correlated with obsession and
phobia. Journal of the European Academy of Dermatology and Venereology 2012; 26
(7), 861-867. *Participated extensively in conception, drafting, reviewing and critical
revision of the manuscript.
120. Pallanti S, Salerno L. Pharmacological treatment and management of attention
deficit hyperactivity disorder (ADHD) in adults. Minerva Psichiatrica 2013 Dec;
54(4);297-315. ISSN: 1827-1731
121. Pallanti. S. The Placebo Effect in Clinical Practice. American Journal of
Psychiatry 2013 170:8, 931-932
122. Bandinelli F, Prignano F, Bonciani D, Pallanti S, Lotti T, Salaffi F, Bartoli F, Candelieri
A, Giovannini L, Maddali Bongi S, Matucci-Cerinic M. Clinical and demographic
factors influence on anxiety and depression in early psoriatic arthritis (ePsA). Clinical
and Experimental Rheumatology. 2012;31(2):318-9. *Participated extensively in
conception, drafting, reviewing and critical revision of the manuscript
123. Pallanti, S., Grassi, G. and Cantisani, A. (2012). Approaches to Treatment
Resistance. In Obsessive-Compulsive Disorder, J. Zohar (Ed.)
https://doi.org/10.1002/9781119941125.ch5
124. Baldwin DS, Pallanti S, Zwanzger P. Developing a European Research Network to
Address Unmet Needs in Anxiety Disorders. Neuroscience and Biobehavioral
Reviews. 2013; 37(10 Pt 1):2312-7. *Participated extensively in conception and trial
design, participated in drafting, reviewing and critical revision of the manuscript
125. Valenti R, Salvadori E, Pescini F, Poggesi A, Castellini G, Antonini S, Bianchi S,
Inzitari D, Pallanti S, Pantoni L., Facial Affect Recognition in CADASIL Patients.,
Archives of Clinical Neuropsychology 2013;28(1):65-71. *Participated extensively in
conception and trial design, participated in drafting, reviewing and critical revision of
the manuscript
126. Berlin HA, Braun A, Simeon D, Koran LM, Potenza MN, McElroy SL, Fong T, Pallanti
S, Hollander E. A double-blind, placebo-controlled trial of topiramate for pathological
gambling. World Journal of Biological Psychiatry. 2013;(2): 121-128. *Participated
extensively in conception and trial design, participated in drafting, reviewing and
critical revision of the manuscript

127. Pallanti S, Cantisani A, Grassi G. Anxiety as a core aspect of schizophrenia. Current
Psychiatry Reports. 2013;15(5):354.
128. Dell’Osso B, Benatti B, Buoli M, Altamura AC, Marazziti D, Hollander E, Fineberg N,
Stein DJ, Pallanti S, Nicolini H, Van Ameringen M, Lochner C, Hranov G,
Karamustafalioglu O, Hranov L, Menchon JM, Zohar J; ICOCS group. The influence
of age at onset and duration of illness on long-term outcome in patients with
obsessive-compulsive disorder, a report from the International College of Obsessive-
Compulsive Spectrum Disorders (ICOCS). European Neuropsychopharmacology.
2013 Aug; 23(8):865 71. *Participated extensively in conception and trial design,
acquisition and analysis of data, participated in drafting, reviewing and critical revision
of the manuscript
129. Pallanti S, Grassi G, Tofani T, Spitoni S. Pharmacological Treatments for Behavioral
Addictions: From Behavioral Dimensions to the Research Domain Criteria Based
Target. Current Psychopharmacology, 2013; 2(3):183-189.
130. Marras A, Pallanti S. Transcranial magnetic stimulation for the treatment of
pharmacoresistant nondelusional auditory verbal hallucinations in dementia. Case
Reports in Psychiatry. 2013; 2013:930304.
131. Pallanti S, Hollander E. Pharmacological, experimental therapeutic, and transcranial
magnetic stimulation treatments for compulsivity and impulsivity. CNS Spectrums.
2014; 19(1):50-61.
132. Carelli R, Pallanti S. Streptococcal infections of skin and PANDAS. Dermatologic
Therapy. 2014 Jan; 27(1):28-30.
133. Grassi G, Poli L, Cantisani A, Righi L, Ferrari G, Pallanti S. Hypocondriasis and
obsessive-compulsive disorder in schizophrenic patients treated with clozapine vs
other atypical antipsychotics. CNS Spectrums. 2014; 9(4):340-6.
134. Van Ameringen S, Simpson W, Patterson B, Dell’Osso B, Finebg n, Hollander E,
Hranov L, Hranov G, Lochner C, Karamustafalioglu O, Marazziti D, Menchon JM,
Nicolini H, Pallanti S, Stein DJ, Zohar, J. Pharmachological treatment strategies in
obsessive-compulsive disorder: A cross-sectional view in nine international OCD
centers. Journal of Psychopharmacology 2014; 28(6):596-602. *Participated
extensively in conception and trial design, authorship of sections of the manuscript,
135. Di Rubbo R., Sogaro E., Pallanti, S. Communicative evolutive psychotherapy
adapted for the psychodynamic group setting in the treatment of pathological
interpersonal dynamics of identity. Dynamische Psychiatrie. 2013; 46(3): 204-233.
136. Pallanti S, Grassi G, Cantisani A. Emerging drugs to treat obsessive-compulsive
disorders. Expert opin Emerg Drugs, 2014 Mar; 19(1):66-77.
137. Pallanti S, Grassi G, Antonini S, Quercioli L, Salvadori E, Hollander E. rTMS in
resistant mixed states: An exploratory study. J Affect Disord. 2014; 157:66-71.
138. Pallanti S, Bernardi S, Antonini S, Singh N, Hollander E. Ondasetron augmentation
in patients with obsessive-compulsive disorder who are inadequate responders to

serotonin reuptake inhibitors: improvement with treatment and worsening following
discontinuation. Eur Neuropsychopharmacol. 2014; 24(3):375-380.
139. Pallanti S, Grassi G, Ramella Cravaro V, Goodman W.K. From Psychopathology to
neurocircuits: what we can learn from DBS? The case of obsessive-compulsive
disorder. J. Psychopathol. 2014; 20:27-32.
140. Aguglia E, Biggio G, Signorelli MS, Mencacci C; Steering Committee on behalf of
the STIMA-D Investigators. Italian Study on Depressive Disorders (STudio Italiano
MAlattia Depressiva, or STIMA-D): a nationwide snapshot of the status of treatment
for major depression. Pharmacopsychiatry.2014 May;47(3), 105-10. *Member:
Pallanti S. *Acquisition of data
141. Pallanti S, Tofani T, Zanardelli M, Di Cesare mannelli L, Ghelardini C. BDNF and
ARTEMIN are increased in drug-naive non-depressed GAD patients: preliminary
data. International Journal of Psychiatry in Clinical Practice. 2014; 18(4):255-60.
142. Lochner C, Fineberg NA, Zohar J, Van Ameringen M, Juven_Wetzler A, Altamura AC
Cuzen NL, Hollander E, Denys D, Nicolini H, Dell'Osso B, Pallanti S, Stein DJ,
Comorbidity in obsessive-compulsive disorder (OCD): a report from the International
College of Obsessive-Compulsive Spectrum Disorder (ICOCS). Comprehensive
Psychiatry. 2014;55(7):1513-9. *Participated extensively in conception and trial
design, drafting, reviewing and critical revision of the manuscript
143. Pallanti S, Grassi G. Pharmacologic treatment of obsessive-compulsive disorder
comorbidity. Expert Opin Pharmacother. 2014;15(17):2543-52.
144. Mucci A, Rucci P, Rocca P, Bucci P, Gibertoni D, Merlotti E, Galderisi S, Maj M;
Italian Network for Research on Psychoses. The Specific Level of Functioning
Scale: construct validity, internal consistency and factor structure in a large Italian
sample of people with schizophrenia living in the community. Schizophrenia
Research. 2014; 159(1):144-50. *Member: Pallanti S. *Acquisition of data
145. Galderisi S, Rossi A, Rocca P, Bertolino A, Mucci A, Bucci P, Rucci P, Gibertoni
D, Aguglia E, Amore M, Bellomo A, Biondi M, Brugnoli R, Dell'Osso L, De Ronchi
D, Di Emidio G, Di Giannantonio M, Fagiolini a, Marchesi C, Monteleone P, Oldani
L, Pinna F, Roncone R, Sacchetti E, Santonastaso P, Siracusano A, Vita A,
Zeppegno P, Maj M; Italian Network for Research on Psychoses. The influence
of illness-related variables, personal resources and context-related factors on
real-life functioning of people with schizophrenia. World Psychiatry. 2014;
13(3):275-87. *Member: Pallanti S. *Acquisition of data
146. Cantisani, A., Grassi, G., Pagano, L., Comanducci, A., Lanzo, G., Amantini, a.,
Grippo, a., Salerno, L., Pallanti, S. Neurophysiological alterations in adults with
attention deficit/hyperactivity disorder: an event-related potential study. European
Neuropsychopharmacology 24:S714-S715 · October 2014. DOI:
10.1016/S0924-977X(14)71151-4
147. Grassi G, Godini L, Grippo A, Piccagliani D, Pallanti S. Enhancing Cognitive-
behavioral Therapy with Repetitive Transcranial Magnetic Stimulation in Refractory
Obsessive-Compulsive-Disorder: a Case Report. Brain Stimulation. 2015; 8(1):160-
1.

148. Pallanti S, Salerno L. Raising attention to attention deficit hyperactivity disorder in
schizophrenia. World Journal of Psychiatry. 2015;5(1):47-55.
149. Grassi, G., Pallanti, S. Citalopram Pulse-Loading for Treatment-Resistant
Obsessive-Compulsive Disorder: Preliminary Data from an Open-Label Trial.
European Neuropsychopharmacology, Volume 26, Issue 5, 2016, Pages 898-899,
ISSN 0924-977X, https://doi.org/10.1016/j.euroneuro.2015.06.034.
150. Dell'Osso B, Nicolini H, Lanzagorta N, Benatti B, Spagnolin G, Palazzo MC, Marazziti
D, Hollander E, Fineberg N, Stein DJ, Pallanti S, Van Ameringen M, Lochner C,
Hranov N, Karamustafalioglu O, Hranov L, Zohar J, Denys d, Altamura AC, Menchon
JM. Cigarette smoking in patients with obsessive compulsive disorder: a report from
International College of Obsessive Compulsive Spectrum Disorder (ICOCS). CNS
Spectrums. 2015; 20(5):469-73. *Participated extensively in conception, participated
in drafting, reviewing and critical revision of the manuscript
151. Uzunova G, Pallanti S, Hollander E. Excitatory/inhibitory imbalance in autism
spectrum disorder: Implications for interventions and therapeutics. World Journal of
Biological Psychiatry. 2015; 15:1-13. *Authorship of sections of the manuscript,
152. Pallanti, S., Grassi G, Marras A, Hollander E. Can we modulate obsessive-
compulsive networks with neuromodulation? J Psychopatol, 21:262-265.
153. Pallanti, S., Marras A, Grassi G. Outcomes with neuromodulation in obsessive-
compulsive disorder. Psych Annals, 45(6):316-320.
154. Pallanti, S., Marras, A. Transcranial Magnetic Stimulation Treatment for Motor
Symptoms in Parkinson's Disease: A Review of Two Decades of Studies. Journal of
Alzheimer’s Disease & Parkinsonism. 05. 10.4172/2161-0460.1000191.
155. Pallanti, S., Marras, A. Transcranial Magnetic Stimulation in Alzheimer’s Disease: A
Review of Investigational and Therapeutic Findings. J Alzheimers Dis Parkinsonism
5:187. doi:10.4172/2161-0460.1000187
156. Grassi, G., Molesti E., Lori S., Pallanti S., Cheli E., Marras A. "OR-38:
neuromodulation of decision-making networks with alfaEEG-guided repetitive
transcranic magnetic stimulation: preliminary results from a pilot study." Journal of
Behavioral Addictions, vol. 5, no. S1, 2016, p. 17+.
157. Grant J E, Fineberg N, Van Ameringen A, Cath D, Visser H, Carmi L, Pallanti S,
Hollander E, Van Balkom A J, New treatment models for compulsive disorders.
European Neuropsychopharmacology 2016; 26(5):877-84. *Participated extensively
in conception, acquisition of data, authorship of sections of the manuscript
158. Grassi G, Pallanti S, Righi L, Figee M, Mantione M, Denys D, Piccagliani D, Rossi
A, Stratta P. Think twice: Impulsivity and decision making in obsessive-compulsive
disorder. Journal of Behavioral Addiction 2015;4(4):263-72. *Provided study ideas,
participated in the drafting, reviewing and revision of the manuscript, and provided
mentorship to first author

159. Pallanti S, Marras A, Salerno L, Makris N, Hollander E. Better than treated as usual:
Transcranial magnetic stimulation augmentation in selective serotonin reuptake
inhibitor-refractory obsessive-compulsive disorder, mini-review, and pilot open-label
trial. Journal of Psychopharmacology. 2016; 30(6):568-78.
160. Menchon JM, Van Ameringen M, Dell’Osso B, Denys D, Figee M, Grant JE, holander
E, Marazziti D, Nicolini H, Pallanti S, Ruck R, stein DJ, Andersson E, bipeta R, Cath
DC, drummond L, Feusner J, Geller DA, Hranov , lochner C, Matsunaga H, McCabe
RE, Mpavaenda D, Nakamae T, O’Kearney R, pasquini M, Perez Rivera R,
Poyurovsky M, Real E, do Rosario MC, Sreni N, Swinson RP, Vulink N, Zphar J,
Fineberg N. Standards of care for obsessive-compulsive disorders centres.
International Journal of Psychiatry in Clinical Practice. 2016;20(3):204-8.
*Participated extensively in conception and trial design, acquisition of data and in
drafting
161. Marras A, Fineberg N, Pallanti S. Obsessive compulsive and related disorders:
comparing DSM-5 and ICD-11. CNS Spectrums. 2016;21(4):324-33.
162. Bandelow B, Baldwin D, Abelli M, Bolea-Alamanac B, bourin M, Chamberlain SR,
Cinosi E, Davies S, Domscchke K, Fineberg N, Grunblatt E, Jarema M, Kim YK,
Maron E, Masdrakis V, Mikova O, Nutt D, Pallanti S, Pini S, Strohle A, Thibaut F,
Vaghi MM, Won E, Wedekind D, Wichniak A, Woolley J, Zwanzger P, Riederer P.
Biological markers for anxiety disordrs, OCD and PTSD: a consensus statement.
Part II: Neurochemistry, neurophisiology and neurocognition. World Journal of
Biological Psychiatry. 2016; 15:1-53. *Participated extensively in conception and trial
design, acquisition,authorship of sections of the manuscript
163. Grassi G, Micheli L, Di Cesare Mannelli L, Compagno E, Righi L, Ghelardini C,
Pallanti S. Atomoxetine for hoarding disorder: A pre-clinical and clinical investigation.
J Psychiatr Res. 2016 Dec;83:240-248. doi: 10.1016/j.jpsychires.2016.09.012. Epub
2016 Sep 14. PMID: 27665536.
164. Dell’Osso B, Benatti B, Hollander E, Fineberg N, Stein DJ, Lochner C, Nicolini H,
Lanzagorta N, Palazzo C, altamura AC, Marazziti D, Pallanti S, Van Ameringen M,
Karamustafalioglu O, Drummond LM, Hrano L, Figee M, Grant JE, Zohar J, Denys
D, Menchon JM. Childhood, adolescent and adult age at onset and related clinical
correlates in obsessive-compulsive disorder: a report from the International College
of Obsessive-Compulsive Spectrum Disorders (ICOCS). International Journal of
Psychiatry in Clinical Practice. 2016; 19:1-8. *Participated extensively in conception
and trial design, acquisition of data and in drafting
165. Pallanti S. ICD and DSM: Neuroplasticity and Staging are still missing. CNS
Spectrums. 2016 Aug:21(4):276-8.
166. Galderisi S, Rossi A, Rocca P, Bertolino A, Mucci A, Bucci P, Rucci P, Gibertoni D,
Aguglia E, Amore M, Blasi G, Comparelli A, Di Giannantonio M, Goracci A, Marchesi
C, Monteleone P, Montemagni C, Pinna F, Roncone R, Siracusano A, Stratta P, Torti
MC, Vita A, Zeppegno P, Chieffi M, Maj M; Italian Network for Research on
Psychoses. Pathways to functional outcome in subjects with schizophrenia living in
the community and their unaffected first-degree relatives. Schizophr Res 2016;
175(1-3):154-60. *Member: Pallanti S. *Participated extensively in conception and

trial design, acquisition, analysis of data, reviewing and critical revision of the
manuscript
167. Rocca P, Galderisi S, Rossi A, Bertolino A, Rucci P, Gibertoni D, Montemagni C,
Sigaudo M, Mucci A, Bucci P, Acciavatti T, Aguglia E, Amore M, Bellomo A, De Ronchi
D, Dell'Osso L, Di Fabio F, Girardi P, Goracci A, Marchesi C, Monteleone P, Niolu C,
Pinna F, Roncone R, Sacchetti E, Santonastaso P, Zeppegno P, Maj M; Italian
Network for Research on Psychoses. Social cognition in people with
schizophrenia: a cluster-analytic approach. Psychol Med 2016 Oct;46(13):2717-2729
*Member: Pallanti S. *Participated extensively in conception and trial design,
acquisition, participated in drafting, reviewing and critical revision of the manuscript
168. Menchón JM, van Ameringen M, Dell'Osso B, Denys D, Figee M, Grant JE, Hollander
E, Marazziti D, Nicolini H, Pallanti S, Ruck C, Shavitt R, Stein DJ, Andersson E,
Bipeta R, Cath DC, Drummond L, Feusner J, Geller DA, Hranov G, Lochner C,
Matsunaga H, McCabe RE, Mpavaenda D, Nakamae T, O'Kearney R, Pasquini M,
Pérez Rivera R, Poyurovsky M, Real E, do Rosário MC, Soreni N, Swinson RP, Vulink
N, Zohar J, Fineberg N. Standards of care for obsessive-compulsive disorder centres.
Int J Psychiatry Clin Pract. 2016 Sep;20(3):204-8. *Participated extensively in
conception and trial design, acquisition of data and in drafting, reviewing and critical
revision of the manuscript
169. Giordano F, Cavallo M, Spacca B, Pallanti S, Tomaiuolo F, Pieraccini F, Fagiolini A,
Grandoni M, Melani F, Zicca A, Sestini S, Genitori L. Deep Brain Stimulation of the
Anterior Limb of the Internal Capsule May Be Efficacious for Explosive Aggressive
Behaviour. Stereotact Funct Neurosurg. 2016 Nov 1;94(6):371-378. *Participated
extensively in conception and trial design, acquisition of data and in drafting
170. Dell'Osso B, Benatti B, Hollander E, Fineberg N, Stein DJ, Lochner C, Nicolini H,
Lanzagorta N, Palazzo C, Altamura AC, Marazziti D, Pallanti S, Van Ameringen M,
Karamustafalioglu O, Drummond LM, Hranov L, Figee M, Grant JE, Zohar J, Denys
D, Menchon JM. Childhood, adolescent and adult age at onset and related clinical
correlates in obsessive-compulsive disorder: a report from the International College
of Obsessive-Compulsive Spectrum Disorders (ICOCS). Int J Psychiatry Clin Pract.
2016 Nov;20(4):210-7. *Participated extensively in conception and trial design,
acquisition of data and in drafting, reviewing and critical revision of the manuscript
171. Grassi G, Micheli L, Di Cesare Mannelli L, Compagno E, Righi L, Ghelardini C,
Pallanti S. Atomoxetine for hoarding disorder: A pre-clinical and clinical investigation.
J Psychiatr Res. 2016 Dec; 83:240-248.
172. Chiariello F, Spitoni S, Hollander E, Pallanti S. An expert opinion on PANDAS/PANS:
highlights and controversies. International Journal of Psychiatry in Clinical Practice
2017; 1-8 Published online: 13 Feb 2017
173. Salerno L, Makris N, Pallanti S. Raadult ADHD: a key feature. Journal of
Psychopathology 2016; 22:135-140.
174. Pallanti S. Biological Markers for Anxiety Disorders, OCD and PTSD – A Consensus
Statement – Part II: Neurochemistry, Neurophysiology and Neurocognition. The
World Journal of Biological Psychiatry World J Biol Psychiatry. 2017 Apr;18(3):162-
214.

175. Dell'Osso B, Benatti B, Arici C, Palazzo C, Altamura AC, Hollander E, Fineberg N,
Stein DJ, Nicolini H, Lanzagorta N, Marazziti D, Pallanti S, van Ameringen M,
Lochner C, Karamustafalioglu O, Hranov L, Figee M, Drummond L, Rodriguez CI,
Grant J, Denys D, Menchon JM, Zohar J. Prevalence of suicide attempt and clinical
characteristics of suicide attempters with obsessive-compulsive disorder: a report
from the International College of Obsessive-Compulsive Spectrum Disorders
(ICOCS). CNS Spectr. 2017 Mar 16:1-8.
176. Dell’Osso B, Marazziti D, Albert U, Pallanti S, Gambini G, Tundo A, Zanaboni C,
Servello D, Rizzo R, Scalone L, Benatti B, Altamura C, Porta M. Parsing the
phenotype of obsessive-compulsive tic disorder (OCTD): a multidisciplinary
consensus. Int J Psychiatry Clin Pract. 2017 Jun;21(2):156-159.
177. Salerno L, Burian I, Pallanti S. A new generation rating scale for depression:
Reliability and Validity of the Italian version of Symptoms of Depression
Questionnaire (SDQ), an RDoC-oriented depression comprehensive assessment.
Journal of Psychopathology, 2017 23:1-12.
178. Grassi, G., Pacini, S., Cecchelli C., Pallanti, S. Enhancing inhibition processes during
cognitive-behavioral therapy in obsessive-compulsive disorder with repetitive
transcranial magnetic stimulation. S1009. European Neuropsychopharmacology,
2017
179. Grassi, G., & Pallanti, S. (2017). Common Neural Networks Between OCD and
Behavioural Addictions: Is LCD a Behavioural Addiction? European Psychiatry,
41(S1), S21-S22. Doi:10.1016/j.eurpsy.2017.01.120
180. Lusicic A, Schruers KR, Pallanti S, Castle DJ. Transcranial magnetic stimulation in
the treatment of obsessive-compulsive disorder: current perspectives.
Neuropsychiatr Dis Treat. 2018 Jun 29;14:1721-1736. doi: 10.2147/NDT.S121140.
PMID: 29988759; PMCID: PMC6029675.
181. Micheli L., Spitoni S, Di Cesare Mannelli L., Billa A.R., Pallanti S. Bacopa Monnieri
as augmentation therapy in the treatment of anhedonia,preclinical and clinical
evaluation. 01 April 2020 http10.1002/ptr.6684
182. Grassi G, Figee M, Ooms P, Righi L, Nakamae T, Pallanti S, Schuurman R, Denys
D. Impulsivity and decision-making in obsessive-compulsive disorder after effective
deep brain stimulation or treatment as usual. CNS Spectr. 2018 Jun 4:1-7
183. Burchi E, Pallanti S. Antibiotics for PANDAS? Limited Evidence: Review and
Putative Mechanisms of Action. Prim Care Companion CNS Disord. 2018 May
3;20(3).
184. Burchi E, Pallanti S. Diagnostic Issues in Early-Onset Obsessive-Compulsive
Disorder and Their Treatment Implications.Curr Neuropharmacol. 2018 Apr 26.
185. Fineberg NA, Chamberlain SR, Menchon J, Demetrovics D, Grünblatt E, Pallanti S,
Carmi L, Billieux J, King D, Dellosso B, Van Ameringen M, Hall N, Potenza M,
Hollander E, Zohar J and the COST Action EU-PUI Network. Manifesto for a

European Research Network into Problematic Usage of the Internet. 2018, in
submission.
186. Fineberg NA, Demetrovics Z, Stein DJ, Ioannidis K, Potenza MN, Grünblatt E, Brand
M, Billieux J, Carmi L, King DL, Grant JE, Yücel M, Dell'Osso B, Rumpf HJ, Hall N,
Hollander E, Goudriaan A, Menchon J, Zohar J, Burkauskas J, Martinotti G, Van
Ameringen M, Corazza O, Pallanti S; COST Action Network, Chamberlain SR.
Version 2. Manifesto for a European research network into Problematic Usage of the
Internet. Eur Neuropsychopharmacol. 2018 Nov;28(11):1232-1246. Doi:
10.1016/j.euroneuro.2018.08.004. Epub 2018 Oct 10. PMID: 30509450
187. Burchi E, Hollander E, Pallanti S. From Treatment Response to Recovery: A Realistic
Goal in OCD. Int J Neuropsychopharmacol. 2018 Nov 1;21 (11):1007-1013. doi:
10.1093/ijnp/pyy079. PMID:30184141
188. Grassi G, Pallanti S. Expert Opinion Pharmacother. 2018 Oct;19(14):1541-1550.
Doi:10.1080/14656566.2018.1528230. Epub 2018 Oct 15. PMID:3021070
189. Sali L, Ventura L, Grazzini G, Borgheresi A, Delsanto S, Falchini M, Mallardi B,
Mantellini P, Milani S, Pallanti S, Zappa M, Mascalchi M. Patients' experience of
screening CT colonography with reduced and full bowel preparation in a randomised
trial. Eur Radiol. 2018 Nov 6. doi: 10.1007/s00330-018-5808-1. [Epub ahead of print]
PMID:30402705
190. Scarpino, M, Lanzo G, Salimova M, Lolli F, Del Vecchio A, Cossu Cesarina,
Bastianelli M, Occupati B, Lanzi C, Pallanti S, Amantini A, Mannaioni G, Grippo A.
Efficacy of high-frequency (15Hz) repetitive transcranial magnetic stimulation (rTMS)
of the left premotor cortex/dorsolateral prefrontal cortex in decreasing cocaine intake
(the Magne Tox study): A study protocol for a randomized placebo-controlled pilot
trial. Neurophysiologie Clinique, 10 2018
191. Grassi, G., Pallanti, S. Current and up-and-coming pharmacotherapy for obsessive-
compulsive disorder in adults, Expert Opinion on Pharmacotherapy, 19:14, 1541-
1550, DOI: 10.1080/14656566.2018.1528230 2018
192. J.J.S. Kooija, D. Bijlengaa, L. Salerno, R. Jaeschkea, I. Bittera, J. Balázsa, J.
Thomea, G. Doma, S. Kaspera, C. Nunes Filipea, S. Stesa, P. Mohra, S.
Leppämäkia, M. Casas Bruguéa, J. Bobesa, J.M. Mccarthya, V. Richartea, A. Kjems
Philipsena, A. Pehlivanidis,b , A. Niemela, B. Styr, B. Semerci, B. Bolea-Alamanac,
D. Edvinsson, D. Baeyens, D. Wynchank, E. Sobanski, A. Philipsen, F. McNicholas,
H. Caci, I. Mihailescu, I. Manor,b , I. Dobrescu,b , J. Krause,b , J. Fayyad, J.A.
Ramos-Quiroga, K. Foeken, F. Rad, M. Adamou, M. Ohlmeier, M. Fitzgerald, M. Gill,
M. Lensing, N. Motavalli Mukaddes, P. Brudkiewicza, P. Gustafsson, P. Tani, P.
Oswald, P.J. Carpentier, P. De Rossi, R. Delorme, S. Markovsk, Simosk, S. Pallanti,
S. Young, S. Bejerot, T. Lehtonen, J. Kustow, U. Müller-Sedgwick, T. Hirvikoski, V.
Pironti, Y. Ginsberg, Z. Félegeházy, M.P. Garcia-Portilla, P. Asherson., Updated
European Consensus Statement on diagnosis and treatment of adult ADHD;
European Psychiatry 56 (2019) 14–34 accepted 3 Nov 2018
193. Fineberg NA, Demetrovics Z, Stein DJ, Ioannidis K, Potenza MN, Grünblatt E, Brand
M, Billieux J, Carmi L, King DL, Grant JE, Yücel M, Dell'Osso B, Rumpf HJ, Hall N,
Hollander E, Goudriaan A, Menchon J, Zohar J, Burkauskas J, Martinotti G, Van

Ameringen M, Corazza O, Pallanti S; COST Action Network, Chamberlain SR.,
Manifesto for a European research network into Problematic Usage of the Internet.
Eur Neuropsychopharmacol. 2018 Nov;28(11):1232-1246. doi:
10.1016/j.euroneuro.2018.08.004. Epub 2018 Oct 10. PMID:30509450
194. Scarpino M, Lanzo G, Salimova M, Lolli F, Del Vecchio A, Cossu C, Bastianelli M,
Occupati B, Lanzi C, Pallanti S, Amantini A, Mannaioni G, Grippo A., Efficacy of high-
frequency (15Hz) repetitive transcranial magnetic stimulation (rTMS) of the left
premotor cortex/dorsolateral prefrontal cortex in decreasing cocaine intake (the
MagneTox Study): A study protocol for a randomized placebo-controlled pilot trial.
Neurophysiol Clin. 2019 Feb;49(1):1-9. doi: 10.1016/j.neucli.2018.10.002. Epub 2018
Oct 26. PMID:30712533
195. Grassi, G., Pacini, S., Cecchelli, C., Pallanti, S. Enhancing Cognitive-Behavioral
Therapy for Obsessive-Compulsive Disorder with Transcranic Magnetic Stimulation:
A proof of concept. European Neuropsychopharmacology, Volume 28, Issue 6, 2018,
Pages 766-767, ISSN 0924-977X, https://doi.org/10.1016/j.euroneuro.2017.10.008.
196. Grassi G., Makris N., Pallanti S. Olfaction in gambling disorder: an exploratory study.
Journal of Behavioral Addictions. ICBA2018 / April 23–25, 2018 / Cologne, Germany.
Vol 7., Supplement 1. www.academiai.com
197. Fineberg NA, Dell'Osso B, Albert U, Maina G, Geller D, Carmi L, Sireau N, Walitza S,
Grassi G, Pallanti S, Hollander E, Brakoulias V, Menchon JM, Marazziti D, Ioannidis
K, Apergis-Schoute A, Stein DJ, Cath DC, Veltman DJ, Van Ameringen M, Fontenelle
LF, Shavitt RG, Costa D, Diniz JB, Zohar J., Early intervention for obsessive
compulsive disorder: An expert consensus statement. Eur Neuropsychopharmacol.
2019 Feb 14. pii: S0924-977X(19)30159-2. doi: 10.1016/j.euroneuro.2019.02.002.
[Epub ahead of print] PMID:30773387
198. HollanderE., Van Ameringen M., Nicolini H., Zohar J., Pallanti S., Nezgoverova V.,
Fineberg N. E. 01.01 Pharmacological Treatment of resistant OCD. European
Neuropsychopharmacology, 2019 vol29, S32, Elsevie
199. Marras A., Gavazzi G., Grassi G., Rathi Y., Mascalchi M., Makris N., Camprodon J.A.,
Pallanti S. Abstract59: Modulating Inhibitory Control Networks in Gambling Disorder
with Theta Burst Stimulation. Brain Stimulation: Basic, Translational, and Clinical
Research in Neuromodulation. Elsevier. 2019 Mar 1., Vol 12, issue 2, e21.
200. Salerno L., Ramat S., Solari G, Grassi G., Pallanti S. Parkinson’s Disease with
Impulse Control Disorders: Higher Prevalence (Frequency) of Symptoms of Attention
Deficit Hyperactivity Disorder International Journal of Clinical Psychiatry 2019, 7(1):
1-7 DOI: 10.5923/j.ijcp.20190701.01
201. Burchi E., Makris N., Lee MR., Pallanti S., Hollander E. Compulsivity in Alcohol Use
Disorder and Obsessive Compulsive Disorder: Implications for Neuromodulation.
2019, Front. Behav. Neurosci. | doi: 10.3389/fnbeh.2019.00070
202. Sacchetti, E. Pallanti, S. Bowden-Jones, H. (2019). Archives of Behavioral
Addictions: A new journal for a new era.Archives of Behavioral Addictions, 1(1).
doi:10.30435/ABA.01.2019.01

203. Grassi G., Makris N., Pallanti S. Addicted to compulsion: assessing three core
dimensions of addiction across obsessive-compulsive disorder and gambling
disorder. CNS Spectr. 2019 May 20:1-10. doi: 10.1017/S1092852919000993. [Epub
ahead of print] PMID:31106718
204. Dell'Osso B., Vismara M., Benatti B., Cirnigliaro G., Grancini B., Fineberg N., Van
Ameringen M., Hollander E., Stein D., Menchon JM., Rodriguez C., Nicolini H.,
Lanzagorta N., Pallanti S., Grassi G., Lochner C., Marazziti D., Hranov G.,
Karamustafalioglu O., Hranov L., Zohar J. Lifetime bipolar disorder comorbidity and
related clinical characteristics in patients with primary obsessive compulsive disorder:
a report from the International College of Obsessive–Compulsive Spectrum
Disorders (ICOCS). CNS Spectrums. doi 10.1017/S1092852919001068 Published
online: 27 May 2019
205. Corponi F, Fabbri C, Bitter I, Montgomery S, Vieta E, Kasper S, Pallanti S, Serretti
A. Novel antipsychotics specificity profile: A clinically oriented review of lurasidone,
brexpprazole, cariprazine and lumateperone. Eur Neuropsychopharmacol. 2019 Jun
26. pii: S0924-977X (19)30266-4. doi: 10.1016/j.euroneuro.2019.06.008. [Epub
ahead of print] Review. PMID:31255396
206. Davis JM. Commentary on: Corponi F., Fabbri C, Bitter, I. Montgomery, S., Vieta, E.,
Kaspar, S., Pallanti S., Serretti A. Novel antipsychotics specificity profile: A clinically
oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. Eur
Neuropsychopharmacol. 2019 Sep;29(9):1061-1062. doi:
10.1016/j.euroneuro.2019.07.001. Epub 2019 Jul 29. No abstract available.
PMID:31371104
207. Kooij JJS, Bijenga D, Salerno L, Jaeschke R, Bitter I, Balazs J, Thome J, Dom G,
Kasper S, Nunes FC, Stes S, Mohr P, Leppamaki S, Casas M, Bobes J, Mccarthy
JM, Richarte V, Kjems PA, Pehlivanidis A, Niemela A, Styr B, Semerci B, Bolea-
Alamanac B, Edvinsson D, Baeyens D, Wynchank D, Sobanski E, Philipsen A,
McNicholas F, Caci H, Mihailescu I, Manor I, Dobrescu I, Saito T, Krause J, Fayyad
J, Ramos-Quiroga JA, Foeken K, Rad F, Adamou M, Ohlmeier M, Fitzgerald M, Gill
M, Lensing M, Motavalli Mukaddes N, Brudkeiwicz P, Gustafsson P, Tani P, Oswald
P, Carpentier PJ, De Rossi P, Delorme R, Markovska Simoska S, Pallanti S, Young
S, Bejerot S, Lehtonen T, Kustow J, Muller-Sedgwick U, Hirvikoski T, Pironti V,
Ginsberg Y, Felegyhazy Z, Garcia-Portilla MP, Asherson P. Updated European
Consensus Statement on diagnosis and treatment of adult ADHD. Eur Psychiatry
2019 Feb; 56:14-34. doi: 10.1016/j.eurpsy.2018.11.001. Epub 2018 Nov 16.
208. Pallanti, S. (2018). Meet our New Field Editor. CNS Spectrums, 23(6), 423-423.
doi:10.1017/S1092852918001530
209. Pasquini M., Brakoulias V., Pallanti S. Editorial: Advances in Biological Approaches
to Treating Resistant/Refractory Obsessive-Compulsive and Related Disorders.
Front Psychiatry. 2020 Feb 25; 11:93. doi: 10.3389/fpsyt.2020.00093. ECollection
2020.
210. Fineberg N.A., Van Ameringen M., Drummond L, Hollander E., Stein D.J. Geller D.,
Walitza S., Pallanti S., Pellegrini L., Zohar J., Rodriguez C.I., Menchon J.M.,
Morgado P., Mpavaenda D., Fontenelle L.F., Feusner J.D., Grassi G., Lochner C.,
Veltman D.J., Sireau N., Carmi L., Adam D., Nicolini H., Dell'Osso B. cu obsessive-

compulsive disorder (OCD) under COVID-19: A clinician's guide from the
International College of Obsessive. Compulsive Spectrum Disorders (ICOCS) and
the Obsessive-Compulsive and Related Disorders Research Network (OCRN) of the
European College of Neuropsychopharmacology.
Doi.org/10.1016/j.comppsych.2020.152174. 0010-440X/© 2020 The Author(s).
Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
211. Fontenelle LF, Oldenhof E, Eduarda Moreira-de-Oliveira M, Abramowitz JS, Antony
MM, Cath D, Carter A, Dougherty D, Ferrão YA, Figee M, Harrison BJ, Hoexter M,
Soo Kwon J, Küelz A, Lazaro L, Lochner C, Marazziti D, Mataix-Cols D, McKay D,
Miguel EC, Morein-Zamir S, Moritz S, Nestadt G, O'Connor K, Pallanti S, Purdon C,
Rauch S, Richter P, Rotge JY, Shavitt RG, Soriano-Mas C, Starcevic V, Stein DJ,
Steketee G, Storch EA, Taylor S, van den Heuvel OA, Veale D, Woods DW, Verdejo-
Garcia A, Yücel M. A Transdiagnostic perspective of constructs underlying
obsessive-compulsive and related idsorders: An international Delphi consensus
study. Aust N Z J Psychiatry. 2020 May 4:4867420912327. doi:
10.1177/0004867420912327. [Epub ahead of print] PMID: 32364439
212. Benatti B, Ferrari S, Grancini B, Girone N, Briguglio M, Marazziti D, Mucci F,
Dell'Osso L, Gambini O, Demartini B, Tundo A, Necci R, De Berardis D, Galentino R,
De Michele S, Albert U, Rigardetto S, Maina G, Grassi G, Pallanti S, Amerio A, Amore
M, Priori A, Servello D, Viganò C, Bosi M, Colombo A, Porta M, Dell'Osso B. Suicidal
ideation and suicidal attempts in patients with obsessive-compulsive tic-related
disorder vs obsessive-compulsive disorder: results of a multicenter Italian study.
CNS Spectr. 2020 May 6:1-8. doi: 10.1017/S1092852920001157. [Epub ahead of
print] PMID: 32372727
213. Galderisi S, Rucci P, Mucci A, Rossi A, Rocca P, Bertolino A, Aguglia E, Amore M,
Bellomo A, Bozzatello P, Bucci P, Carpiniello B, Collantoni E, Cuomo A, Dell'Osso L,
Di Fabio F, di Giannantonio M, Gibertoni D, Giordano GM, Marchesi C, Monteleone
P, Oldani L, Pompili M, Roncone R, Rossi R, Siracusano A, Vita A, Zeppegno P, Maj
M; Italian Network for Research on Psychoses*.The interplay among
psychopathology, personal resources, context-related factors and real-life functioning
in schizophrenia: stability in relationships after 4 years and differences in network
structure between recovered and non-recovered patients. *Member: Pallanti, S.
World Psychiatry. 2020 Feb;19(1):81-91. doi: 10.1002/wps.20700.PMID: 31922687
214. Fontenelle, L. F., Oldenhof, E., Eduarda Moreira-de-Oliveira, M., Abramowitz, J. S.,
Antony, M. M., Cath, D. C., Carter, A., Dougherty, D., Ferrão, Y. A., Figee, M.,
Harrison, B. J., Hoexter, M., Soo Kwon, J., Küelz, A., Lazaro, L., Lochner, C.,
Marazziti, D., Mataix-Cols, D., McKay, D., Miguel, E.C., Morein-Zamir, S., Moritz, S.,
Nestadt, G., O’Connor, K., Pallanti, S., Purdon, C., Rauch, S., Richte, P., Rotge, J.Y.,
Shavitt, R.G., Soriano-Mas, C., Stein, D.J., Steketee, G., Sorch, E.A., Taylor, S., Van
den Heuvel, O.A., Veale, D., Woods, D.W., Verdejo-Garcia, A., Yucel, M. The
International OCRDs Neuroscience Consensus Group (2020). A transdiagnostic
perspective of constructs underlying obsessive-compulsive and related disorders: An
international Delphi consensus study. Australian & New Zealand Journal of
Psychiatry, 54(7), 719-731. https://doi.org/10.1177/0004867420912327
215. Sali, L., Ventura, L., Grazzini, G., Borgherese, A., Delsanto, S., Falchini, M., Mallardi,
B., Mantellini, P., Milani, S., Pallanti, S., Zappa M., Mascalchi M. Patients’ experience

of screening CT colonography with reduced and full bowel preparation in a
randomised trial. Eur Radiol 29, 2457–2464 (2019). https://doi.org/10.1007/s00330-
018-5808-1
216. Fineberg, Naomi A., Hollander, Eric., Pallanti, Stefano., Walitza, Susanne Grünblatt,
Ednag,,h,,i; Dell’Osso, Bernardo Mariaj,,k,,l,,m; Albert, Umberton; Geller, Daniel A.o;
Brakoulias, Vlasiosp,,q; Janardhan Reddy, Y.C.r; Arumugham, Shyam Sundarr;
Shavitt, Roseli G.s; Drummond, Lynnet; Grancini, Benedettab,,j; De Carlo, Verab,,j;
Cinosi, Eduardoa,,b; Chamberlain, Samuel R.u,,v; Ioannidis, Konstantinosu,,v;
Rodriguez, Carolyn I.k,,w; Garg, Kabirb; Castle, Davidx; Van Ameringen, Michaely,,z;
Stein, Dan J.aa; Carmi, Liorbb,,cc; Zohar, Josephbb,,dd; Menchon, Jose M.ee Clinical
advances in obsessive-compulsive disorder: a position statement by the International
College of Obsessive-Compulsive Spectrum Disorders, International Clinical
Psychopharmacology: July 2020 - Volume 35 - Issue 4 - p 173-193 doi:
10.1097/YIC.0000000000000314
217. Pallanti S. Importance of SARs-Cov-2 anosmia: From phenomenology to
neurobiology. Compr.Psychiatry.2020;100:152184.Doi:
10.1016/j.comppsych.2020.152184
218. Pallanti S, Grassi E, Makris N, Gasic GP, Hollander E. Neurocovid-19: A clinical
neuroscience-based approach to reduce SARS-CoV-2 related mental health
sequelae [published online ahead of print, 2020 Aug 15]. J Psychiatr Res.
2020;130:215-217. doi: 10.1016/j.jpsychires.2020.08.008
219. Netto, V.D.M., Flores, C., Pallanti, S. Pharmacological Treatment for Comorbid
Bipolar Disorder and Obsessive-Compulsive Disorder in Adults, Journal of
Psychiatric Practice: September 2020 - Volume 26 - Issue 5 - p 383-393. doi:
10.1097/PRA.0000000000000499
220. Gaur S, Pallanti S. Treatment Outcomes in an Adult Attention Deficit Hyperactivity
Disorder Clinic with a Focus on Executive Functioning and Sluggish Cognitive Tempo.
Cureus 12(8): e9814. doi: 10.7759/cureus.9814
221. Pallanti, S., Porta, F., Salerno, L., Adult attention deficit hyperactivity disorder in
patients with fibromyalgia syndrome: Assessment and disabilities, Journal of
Psychiatric Research, 2020, ISSN 0022-3956,
https://doi.org/10.1016/j.jpsychires.2020.10.027.
(http://www.sciencedirect.com/science/article/pii/S002239562031030X)
222. Castro-Calvo, J., King, D. L., Stein, D. J., Brand, M., Carmi, L., Chamberlain, S.
R., Demetrovics, Z., Fineberg, N. A., Rumpf, H.-J., Yücel, M., Achab, S., Ambekar,
A., Bahar, N., Blaszczynski, A., Bowden-Jones, H., Carbonell, X., Chan, E. M. L., Ko,
C.-H., de Timary, P., Dufour, M., Grall-Bronnec, M., Lee, H. K., Higuchi, S., Jimenez-
Murcia, S., Király, O., Kuss, D. J., Long, J., Müller, A., Pallanti, S., Potenza, M.
N., Rahimi-Movaghar, A., Saunders, J. B., Schimmenti, A., Lee, S.-Y., Siste,
K., Spritzer, D. T., Starcevic, V., Weinstein, A. M., Wölfling, K., and Billieux,
J. (2021) Expert appraisal of criteria for assessing gaming disorder: An international
Delphi study. Addiction, https://doi.org/10.1111/add.15411.

223. Correll, CU., Demyttenaere, K., Fagiolini, A., Hajak, G., Pallanti, S., Racagni, G.,
Singh, S. Future Neurology 2020 15:4. 30 Nov 2020 https://doi.org/10.2217/fnl-2020-
0012
224. Micheli, L, Spitoni, S, Di Cesare Mannelli, L, Bilia, AR, Ghelardini, C, Pallanti,
S. Bacopa monnieri as augmentation therapy in the treatment of anhedonia,
preclinical and clinical evaluation. Phytotherapy
Research. 2020; 34: 2331– 2340. https://doi.org/10.1002/ptr.6684
225. Fineberg, N. A., Van Ameringen, M., Drummond, L., Hollander, E., Stein, D. J.,
Geller, D., Walitza, S., Pallanti, S., Pellegrini, L., Zohar, J., Rodriguez, C. I.,
Menchon, J. M., Morgado, P., Mpavaenda, D., Fontenelle, L. F., Feusner, J. D.,
Grassi, G., Lochner, C., Veltman, D. J., Sireau, N., … Dell'Osso, B. (2020). How to
manage obsessive-compulsive disorder (OCD) under COVID-19: A clinician's guide
from the International College of Obsessive Compulsive Spectrum Disorders
(ICOCS) and the Obsessive-Compulsive and Related Disorders Research Network
(OCRN) of the European College of Neuropsychopharmacology. Comprehensive
psychiatry, 100, 152174. https://doi.org/10.1016/j.comppsych.2020.152174
226. Uzunova, G., Pallanti, S., Hollander, E. (2021) Presentation and management of
anxiety in individuals with acute symptomatic or asymptomatic COVID-19 infection,
and in the post-COVID-19 recovery phase, International Journal of Psychiatry in
Clinical Practice, DOI: 10.1080/13651501.2021.1887264
227. Lolli F, Salimova M, Scarpino M, Lanzo G, Cossu C, Bastianelli M, Occupati B, Gori
F, Del Vecchio A, Ercolini A, Pascolo S, Cimino V, Meneghin N, Fierini F, D'Anna G,
Innocenti M, Ballerini A, Pallanti S, Grippo A, Mannaioni G. A randomised, double-
blind, sham-controlled study of left prefrontal cortex 15 Hz repetitive transcranial
magnetic stimulation in cocaine consumption and craving. PLoS One. 2021 Nov
16;16(11):e0259860. doi: 10.1371/journal.pone.0259860. PMID: 34784373.
228. Nezgovorova, V., Ferretti, CJ., Pallanti, S., Hollander, E. Modulating
neuroinflammation in COVID-19 patients with obsessive-compulsive disorder,
Journal of Psychiatric Research,2021, ISSN 0022-3956,
229. Pallanti, S., Marras, A., & Makris, N. (2021). A Research Domain Criteria Approach
to Gambling Disorder and Behavioral Addictions: Decision-Making, Response
Inhibition, and the Role of Cannabidiol. Frontiers in psychiatry, 12, 634418.
https://doi.org/10.3389/fpsyt.2021.634418
230. Castle D, Beilharz F, Phillips KA, Brakoulias V, Drummond LM, Hollander E,
Ioannidis K, Pallanti S, Chamberlain SR, Rossell SL, Veale D, Wilhelm S, Van
Ameringen M, Dell'Osso B, Menchon JM, Fineberg NA. Body dysmorphic disorder:
a treatment synthesis and consensus on behalf of the International College of
Obsessive-Compulsive Spectrum Disorders and the Obsessive Compulsive and
Related Disorders Network of the European College of
Neuropsychopharmacology (Pallanti, S.) Int Clin Psychopharmacol. 2021 Mar
1;36(2):61-75. doi: 10.1097/YIC.0000000000000342. PMID: 33230025; PMCID:
PMC7846290.

231. Bentatti, B., Dell’Osso, B., Shen, H., Filippou-Frye, M., Varias, A., Sanchez, C., Jo,
Booil., Hollander, E., Fineberg, NA., Stein, DJ., Nicolini, H., Lanzagorta, N.,
Marazziti, D., Pallanti, S., Van Ameringen, M., Lochner, C., Karamustafalioglu, O.,
Hranov, L., Figee, M., Drummond, L., Grant, JE., Denys D., Fontenelle LF.,
Menchon JM., Zohar, J., Pellegrini, L., Rodriguez, C. Prevalence and correlates of
current suicide risk in an international sample of OCD adults: A report from the
International College of Obsessive-Compulsive Spectrum Disorders (ICOCS)
network and Obsessive Compulsive and Related Disorders Network (OCRN) of the
European College of Neuropsychopharmacology, Journal of Psychiatric Research,
Volume 140, 2021, Pages 357-363, ISSN 0022-3956,
232. Salerno L., Pallanti S. COVID-19 Related Distress in Gambling Disorder. Frontiers
in Psychiatry. VOLUME12. 2021. pp156.
https://www.frontiersin.org/article/10.3389/fpsyt.2021.620661.
DOI10.3389/fpsyt.2021.620661. ISSN1664-0640
233. Grassi, G., Figee, M., Stratta, P., Rossi, A., & Pallanti, S. Response to Cognitive
impulsivity and the behavioral addiction model of obsessive–compulsive disorder:
Abramovitch and McKay (2016), Journal of Behavioral Addictions J Behav
Addict, 5(3), 398-400. Retrieved Apr 9, 2021,
from https://akjournals.com/view/journals/2006/5/3/article-p398.xml
234. Pallanti S, Salerno L. ADHD: the dark side of Eating Disorders. Evidence-
based Psychiatric Care 2016;2;24-31, http:/ www.evidence-based-
psychiatric-care.org/wp-content/uploads/2016/07/05_pallanti.pdf. ISSN: 2421-
4469
235. Benatti, B., Girone, N., Conti, D., Cafaro, R., Vigano, C., Briguglio, M., Marazziti, D.,
Mucci, F., Gambini, O., Demartini, B., Tundo, A., Necci, R., De Berardis, D.,
Galentino, R., De Michele, S., Balestrino, R., Albert U., Rogardetto S., Mania, G.,
Grassi, G., Pallanti, S., Amerio, A., Aguglia, A., Presta, D., Amore, M., Priori, A.,
Servello, D., Porta, M., Dell’Osso, B. (2021). Assessing response, remission and
treatment resistance in patients with Obsessive-Compulsive Disorder with and
without Tic Disorders: results from a multicenter study. CNS Spectrums, 1-22.
Doi:10.1017/S109285292100081X
236. Pallanti, S., Marras, A., Dickson, S. L., Adan, R. A. H., Vieta, E., Dell Osso, B.,
Arango, C., Fusar-Poli, P., Soriano-Mas, C., Carmi, L., Meyer Lindenberg, A., Zohar,
J. Manifesto for an ECNP Neuromodulation Thematic Working Group (TWG): Non-
invasive brain stimulation as a new Super-subspecialty, European
Neuropsychopharmacology, Volume 52, 2021, Pages 72-83, ISSN 0924-977X,
https://doi.org/10.1016/j.euroneuro.2021.07.002.
(https://www.sciencedirect.com/science/article/pii/S0924977X21002728)
237. Castle, D., Beilharz, F., Phillips, K. A., Brakoulias, V., Drummond, L. M., Hollander,
E., Ioannidis, K., Pallanti, S., Chamberlain, S. R., Rossell, S. L., Veale, D., Wilhelm,
S., Van Ameringen, M., Dell'Osso, B., Menchon, J. M., & Fineberg, N. A. (2021).
Body dysmorphic disorder: a treatment synthesis and consensus on behalf of the
International College of Obsessive-Compulsive Spectrum Disorders and the
Obsessive Compulsive and Related Disorders Network of the European College of

Neuropsychopharmacology. International clinical psychopharmacology, 36(2), 61–
75. https://doi.org/10.1097/YIC.0000000000000342
238. Correll, CU., Demyttenaere, K., Fagiolini, A., Hajak, G., Pallanti, S., Racagni, G.,
Singh, S. Cariprazine in the management of negative symptoms of schizophrenia:
state of the art and future perspectives. Future Neurology 2020 15:4. 30 Nov 2020
https://doi.org/10.2217/fnl-2020-0012
239. Sforzini L, Worrell C, Kose M, Anderson IM, Aouizerate B, Arolt V, Bauer M, Baune
BT, Blier P, Cleare AJ, Cowen PJ, Dinan TG, Fagiolini A, Ferrier IN, Hegerl U,
Krystal AD, Leboyer M, McAllister-Williams RH, McIntyre RS, Meyer-Lindenberg A,
Miller AH, Nemeroff CB, Normann C, Nutt D, Pallanti S, Pani L, Penninx BWJH,
Schatzberg AF, Shelton RC, Yatham LN, Young AH, Zahn R, Aislaitner G, Butlen-
Ducuing F, Fletcher C, Haberkamp M, Laughren T, Mäntylä FL, Schruers K,
Thomson A, Arteaga-Henríquez G, Benedetti F, Cash-Gibson L, Chae WR, De
Smedt H, Gold SM, Hoogendijk WJG, Mondragón VJ, Maron E, Martynowicz J,
Melloni E, Otte C, Perez-Fuentes G, Poletti S, Schmidt ME, van de Ketterij E, Woo
K, Flossbach Y, Ramos-Quiroga JA, Savitz AJ, Pariante CM. A Delphi-method-
based consensus guideline for definition of treatment-resistant depression for
clinical trials. Mol Psychiatry. 2021 Dec 15. doi: 10.1038/s41380-021-01381-x. Epub
ahead of print. PMID: 34907394.
240. Castle, D., Beilharz, F., Phillips, K. A., Brakoulias, V., Drummond, L. M., Hollander,
E., Ioannidis, K., Pallanti, S., Chamberlain, S. R., Rossell, S. L., Veale, D., Wilhelm,
S., Van Ameringen, M., Dell'Osso, B., Menchon, J. M., & Fineberg, N. A. (2021).
Body dysmorphic disorder: a treatment synthesis and consensus on behalf of the
International College of Obsessive-Compulsive Spectrum Disorders and the
Obsessive Compulsive and Related Disorders Network of the European College of
Neuropsychopharmacology. International clinical psychopharmacology, 36(2), 61–
75. https://doi.org/10.1097/YIC.0000000000000342
241. Pallanti S. Neuromodulation; TMS (Transcranial Magnetic Stimulation) and the
other Non Invasive Brain Stimulation (NIBS) in the era of brain connectivity. Eur
Neuropsychopharmacol. 2021 Apr;45 38. doi:10.1016/j.euroneuro.2021.03.004.
PMID: 33745763.
242. Lolli F, Salimova M, Scarpino M, Lanzo G, Cossu C, Pallanti S., Mannaioni, G.
et.al. (2021) A randomised, double-blind, sham-controlled study of left prefrontal
cortex 15 Hz repetitive transcranial magnetic stimulation in cocaine consumption
and craving. PLOS ONE 16(11):
e0259860. https://doi.org/10.1371/journal.pone.0259860
243. Benatti, B., Girone, N., Conti, D., Cafaro, R., Viganò, C., Briguglio, M., Pallanti S.,
Dell’Osso, B. et.al. (2021). Assessing response, remission, and treatment
resistance in patients with obsessive–compulsive disorder with and without tic
disorders: Results from a multicenter study. CNS Spectrums, 1-7.
doi:10.1017/S109285292100081X
244. Benatti, B., Dell'Osso, B., Shen, H., Filippou-Frye, M., Varias, A., Sanchez, Booil Jo,
C., Hollander, E., Fineberg, NA., Stein, DJ., Nicolini, H., Lanzagorta, N., Marazziti,
D., Pallanti, S., Van Ameringen, M., Lochner, C., Karamustafalioglu, O., Hranov, L.,
Figee, M., L., Drummond, Grant, JE., Denys, D., Fontenelle, LF., Menchon, JM.,

Zohar, J., Pellegrini, L., Rodriguez, CI. Prevalence and correlates of current suicide
risk in an international sample of OCD adults: A report from the International
College of Obsessive-Compulsive Spectrum Disorders (ICOCS) network and
Obsessive Compulsive and Related Disorders Network (OCRN) of the European
College of Neuropsychopharmacology, Journal of Psychiatric Research,Volume
140, 2021, Pages 357-363, ISSN 0022-3956,
245. Benatti, B., Ferrari, S., Grancini, B., Girone, N., Briguglio, M., Marazziti, D., Pallanti.
S., Dell’Osso, B. et.al. (2021). Suicidal ideation and suicidal attempts in patients
with obsessive-compulsive tic-related disorder vs obsessive-compulsive disorder:
Results of a multicenter Italian study. CNS Spectrums, 26(4), 354-361.
doi:10.1017/S1092852920001157
246. Pallanti, S., Makris, N., Camprodon, J., Rathi, Y., Salerno, L., Marras, A., &
Gavazzi, G. (2021). P. 0611 Theta burst stimulation of the pre-supplementary motor
area in gambling disorder: preliminary data on gambling severity and clinical global
impression. European Neuropsychopharmacology, 53, S449.
247. Van Ameringen, M., Patterson, B., Turna, J., Lethbridge, G., Bergmann, C. G.,
Lamberti, N., S Pallanti, G Grassi, M Vismara, Umberto Albert, R Gedanke Shavitt,
E Hollander, J Feusner, CI Rodriguez, Pedro Morgado Dell’Osso, B. (2022).
Obsessive-compulsive disorder during the COVID-19 pandemic. Journal of
Psychiatric Research.
248. Benatti B., Girone N., Celebre L., Vismara, M., Hollander, E., Fineberg, NA., Stein,
DA., Nicolini, H., Lanzagorta, N., Marazziti, D., Pallanti, S., Van Ameringen, M.,
Lochner, C., Karamustafalioglu,O., Hranov, L., Figee, M., Drummond, LM., Grant,
JE., Denys, D., Fontenelle, LF., Menchon, JM., Zohar, J., Rodriguez, CI., Dell'Osso,
B. The role of gender in a large international OCD sample: A Report from the
International College of Obsessive-Compulsive Spectrum Disorders (ICOCS)
Network, Comprehensive Psychiatry, 2022, 152315, ISSN 0010-440X,
https://doi.org/10.1016/j.comppsych.2022.152315. PMID: 35483201.
(https://www.sciencedirect.com/science/article/pii/S0010440X22000219)
249. Pallanti, S., Ponzio, M., Grassi, E., Vannini, G., Cauli, G. Transcranial
Photobiomodulation for the Treatment of Children with Autism Spectrum Disorder
(ASD): A Retrospective Study. Children 2022, 9, 755.
https://doi.org/10.3390/children9050755
250. Salerno, L., Grassi, E., Makris, N, Pallanti, S. “A Theta Burst Stimulation on Pre-
SMA: Proof-of-Concept of Transcranial Magnetic Stimulation in Gambling
Disorder”. J Gambl Stud (2022). https://doi.org/10.1007/s10899-022-10129-3
251. Borwin Bandelow, Christer Allgulander, David S. Baldwin, Daniel Lucas da
Conceição Costa, Damiaan Denys, Nesrin Dilbaz, Katharina Domschke, Elias
Eriksson, Naomi A. Fineberg, Josef Hättenschwiler, Eric Hollander, Hisanobu Kaiya,
Tatiana Karavaeva, Siegfried Kasper, Martin Katzman, Yong-Ku Kim, Takeshi Inoue,
Leslie Lim, Vasilios Masdrakis, José M. Menchón, Euripedes C. Miguel, Hans-
Jürgen Möller, Antonio E. Nardi, Stefano Pallanti, Giampaolo Perna, Dan Rujescu,
Vladan Starcevic, Dan J. Stein, Shih-Jen Tsai, Michael Van Ameringen, Anna
Vasileva, Zhen Wang & Joseph Zohar (2022) World Federation of Societies of

Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-
compulsive and posttraumatic stress disorders – Version 3. Part I: Anxiety
disorders, The World Journal of Biological
Psychiatry, DOI: 10.1080/15622975.2022.2086295
252. Ilenia Pampaloni, Sabina Marriott, Enrico Pessina, Claire Fisher, Anusha Govender,
Heba Mohammed, Augusta Chandler, Himanshu Tyagi, Lucy Morris, Stefano
Pallanti, The global assessment of OCD, Comprehensive Psychiatry, 2022,
152342, ISSN 0010-440X,
https://doi.org/10.1016/j.comppsych.2022.152342.(https://www.sciencedirect.com/s
cience/article/pii/S0010440X22000487)
Peer-Reviewed Editorials
1. Pallanti S. The anxiety-psychosis spectrum. CNS Spectrums. 2000 Sep;5(9):22.
2. Pallanti S., Transcultural Observations of Obsessive-Compulsive disorder,
American Journal of Psychiatry, 165:2, February 2008
3. Pallanti S., Problematic Internet Use: is it more compulsory than rewarding or
mood driven? World Psychiatry.2010 Jun;9(2):96-7.
4. Pallanti S. Transcultural observations of obsessive-compulsive disorder. American
Journal of Psychiatry. 2008 Feb;165(2):169-70.
5. Pallanti S. Problematic Internet use: is it more compulsory than rewarding or mood
driven? World Psychiatry. 2010 Jun;9(2):96-7.
6. Grassi G, Godini L, Grippo A, Piccagliani D, Pallanti S. Enhancing Cognitive-
behavioral Therapy with Repetitive Transcranial Magnetic Stimulation in Refractory
Obsessive-Compulsive-Disorder: a Case Report. Brain Stimulation.2014.10.18.
7. Pasquini M., Brakoulias V., Pallanti S. Editorial: Advances in Biological Approaches
to Treating Resistant/Refractory Obsessive-Compulsive and Related Disorders.
Front. Psychiatry 11:93. doi: 10.3389/fpsyt.2020.00093
8. Pallanti S. Neuromodulation; TMS (Transcranial Magnetic Stimulation) and the
other Non-Invasive Brain Stimulation (NIBS) in the era of brain connectivity,
European Neuropsychopharmacology, Elsevier, Editorial.
https://doi.org/10.1016/j.euroneuro.2021.03.004
9. Pallanti, S. (2018). Meet our New Field Editor. CNS Spectrums, 23(6), 423-423.
doi:10.1017/S1092852918001530
Peer-Reviewed Abstracts
1. Pallanti S., Zuccarini S., Rivelli A., Quercioli L., Pazzagli A. Depth perception in
schizophrenia. Biological Psychiatry 35 (9), 637-638. 1994-05-01.

2. Koran L., Sallee F., Pallanti S., Paiva R., Quercioli L. Intravenous pulse loading of
clomipramine in obsessive-compulsive disorder. Psychopharmacology Bulletin 32
(3), 466-466. Nov. 1996.
3. Di Russo F., Zaccara G., Pallanti S., Gangemi P., Lori S., Ragazzoni A. Visual event-
related potentials in obsessive-compulsive disorders. Electroencephalography and
Clinical Neurophysiology 103 (1), 211-211, Jul 1997.
4. Pallanti S., Quercioli L. Objective and subjective investigation of cognitive deficits in
young schizophrenic patients. Journal of Psychophysiology 13 (3), 203-203, 1999-
01-01.
5. Russo F., Zaccara G., Ragazzoni A. Pallanti S. Abnormal visual ERPs in obsessive-
compulsive deficits in young schizophrenic patients. Journal of Psychophysiology 13
(3), 207-207, 1999-01-01.
6. Pallanti S., Quercioli L. Reboxetine in bulimia nervosa: An open study. Biological
Psychiatry 49 (8), 105S-106S. 2001-04-05.
7. Quercioli L., Bruscoli M., Pallanti S. P.1.030 Mirtazapine augmentation of citalopram
response in OCD patients without comorbid depression: A pilot study. European
8. Pallanti S., Quercioli L. Reboxetine in bulimia nervosa: An open study. Biological
Psychiatry 49 (8), 105S-106S. 2001-04-05.
9. Quercioli L., Bruscoli M., Pallanti S. P.1.030 Mirtazapine augmentation of citalopram
response in OCD patients without comorbid depression: A pilot study. European
10. Pallanti S., Baker B.R., Chaplin W., Kim S., De Caria C., Bernardi S., Hollander E.,
Noradrenergic function in pathological gambling. Biological Psychiatry. 2006;59 (8),
32S-32S.
11. Bernardi S., Ramat S., Raglione L., Marini P., Sorbi S., Ammannati F., Pallanti S.
Punding after bilateral subthalamic nucleus stimulation in Parkinson’s disease.
European Psychiatry 23, S350-S351.
12. Cincotta M., Borgheresi A., Pampaloni I., Giovannelli F., Bernardi S., Cantisani A.,
Zaccara G., Pallanti S. P27-7 Motor cortex excitability correlates with novelty seeking
in social anxiety: a transcranial magnetic stimulation study. Clinical Neurophysiology
121, s265, 2010-20-31.
Peer-Reviewed Letters and Commentary
1. Marazziti D, Pallanti S. Effectiveness of olanzapine treatment for severe obsessive-
compulsive disorder. American Journal of Psychiatry. 1999 Nov;156(11):1834-5.
2. Pallanti S. "Dr. Pallanti Replies." American Journal of Psychiatry, 2000 157(5):840-
a–840.

3. Hollander E, Pallanti S. "5-HT1D Function and Repetitive Behaviors." American
Journal of Psychiatry, 2001 158(6):972-a–973.
4. Pallanti S, Quercioli L, Hollander E. "Dr. Pallanti and Colleague Reply." American
Journal of Psychiatry, 2005 162(2): 400-a–401.
5. Faravelli C., Pallanti S., Biondi F., Paterniti S., Scarpato M.A. Dr. Faravelli and
Associates Reply. American Journal of Psychiatry 150 (9), 1437-1437. 1993-09-01.
6. Grassi G, Figee M, Stratta P, Rossi A, Pallanti S. Response to Cognitive impulsivity
and the behavioral addiction model of obsessive-compulsive disorder: Abramovitch
and McKay (2016). J Behav Addict. 2016 Sep;5(3):398-400.
7. Koran LM, Faravelli C, Pallanti S. Intravenous clomipramine for obsessive-
compulsive disorder. Journal of Clinical Psychopharmacology 1994 Jun;14(3):216-8
8. Marazziti D, Pallanti S. Effectiveness of olanzapine treatment for severe obsessive-
compulsive disorder. American Journal of Psychiatry. 1999 Nov;156(11):1834-5.
9. Hollander E, Pallanti S. 5-HT(1D) function and repetitive behaviors. American
Journal of Psychiatry. 2001 Jun;158(6):972-3.
10. Pallanti S, Koran LM. Citalopram and sexual side effects of selective serotonin
reuptake inhibitors. American Journal of Psychiatry. 1999 May;156(5):796.
Peer-Reviewed Book Reviews
1. Pallanti S. Obsessive-Compulsive Disorder: Theory, Research, and Treatment.
American Journal of Psychiatry 1999; 156:1108a-1109.
2. Pallanti S. Panic Disorder: Clinical Diagnosis, Management and Mechanism.
American Journal of Psychiatry 158(7), 1176-a-1177. 2001-07-01. Book Review
3. Pallanti S. Panic Disorder: Clinical Diagnosis, Management and Mechanism.
American Journal of Psychiatry 158(7), 1176-a-1177. 2001-07-01.
4. Pallanti S. Review of perfectionism: theory, research and treatment. American
Journal of Psychiatry 2004, vol.161 (8).
Other Publications
1. Pallanti S. Vincenzo Chiarugi, 1759-1820. American Journal of Psychiatry. 1996
Jul;153(7):944.
2. Pallanti S. Images in Psychiatry. Ugo Cerletti. 1877-1963 Essay. American Journal
of Psychiatry 156.630-630, 1999.
3. Pallanti S. Obsessive-Compulsive Disorder: Theory, Research, and Treatment.
American Journal of Psychiatry 1999; 156:1108a-1109

4. Pallanti S., Quercioli L. SSRIs in the treatment of premenstrual dysphoric disorder.
Nefazodone: An open trial. European Neuropsychopharmacology 10(S3), 127-128,
2000-09-30
5. Pallanti S. Pathological Gambling, A clinical guide to treatment, American Psychiatric
Publishing, 2004, Introduction
6. Pallanti S. From impulse-control disorders toward behavioral addictions. CNS
Spectrums. 2006;11(12).921-922.
7. Pallanti S. Unique contributions of brain stimulation to the study of consciousness:
where neuroscience meets philosophy. CNS Spectrums. 2010 Mar;15(3):154-6.
8. Pallanti S., Book Review: Comprehensive care of schizophrenia: a textbook of
clinical management, 2nd edition. American Journal of Psychiatry. 2013 Jan
1;170(1):125-126.
9. Pallanti S., Strategies for Treatment Resistant OCD, Psychiatric Times. 2014.
Book Chapters
1. Pallanti S., Rossi L., De Palma G., Checchi M., Muscas C., Faravelli C.
Electroencephalogram mapping in sodium lactate-induced panic attacks: Preliminary
results. Imaging of the Brain in Psychiatry and Related Fields, pp 281-284, Edited
by K. Maurer, Springer, 1993
2. Current and Experimental Therapeutics of Obsessive Compulsive Disorders, pp 1647
– 1664, Neuropsychopharmacology: The Fifth Generation of Progress, An Official
Publication of the American College of Neuropsychopharmacology, Edited by
K.L. Davis, D. Charney, J.T. Coyle and C. Nemeroff, Lippincott/Williams and Wilkins,
2002
3. Psychobiology of Impulse Control Disorders Not Otherwise Specified (NOS), pp 1315
– 1329, Biological Psychiatry, Edited by H. D’Haenen, J.A. den Boer, P. Willner,
John Wiley & Sons Ltd., 2002
4. Sood E, Pallanti S, Hollander E. Serotonin reuptake inhibitors in the treatment of
pathological gambling. Essential Psychopharmacology, pp 157-169, Edited by R.
Murray, Cambridge University Press, 2002
5. Pharmacological Treatments, pp 189 – 200, Pathological Gambling: A Clinical
Guide to Treatment, Edited by J. E. Grant, M. Potenza, American Psychiatric
Publishing, 2004
6. Pathological Gambling, pp 251 – 289, Clinical Manual of Impulse Control
Disorders, Edited by E. Hollander, D. Stein, American Psychiatric Publishing, 2006
7. Approaches to treatment resistance, pp. 99-117, Obsessive Compulsive Disorder:
Current Science and Clinical Practice, Edited by J. Zohar, John Wiley & Sons, LTD,
2012
8. Positron Emission Tomography. Edited by Miscaglia, S. pp.177 – 188. Chapter 7,
Santoro D., Pallanti S. Pathological Gambling: PET Studies. December 18th 2013

DOI: 10.5772/57537 ISBN: 978-953-51-1213-6 eBook (PDF) ISBN: 978-953-51-
7188-1 Copyright year: 2013
9. Pharmacological treatment of Autism Spectrum Disorders, pp. 151 – 166, Autism
Spectrum Disorders- Phenotypes, Mechanisms and treatment, Edited by M.
Leboyer, P. Chaste, Karger Medical and Scientific Publishers, 2015
10.New Technologies in Autism: Non-invasive Brain Stimulation, Autism Spectrum
Disorders, Enticott PG, Pallanti S, Ring R, Pascual-Leone A, Hollander E., Edited
by E. Hollander, D. Fein, P.J. Hagerman. Karger Medical and Scientific Publishers,
2017 [in press]
11.Incompleteness and Harm Avoidance in OCD, pp. Obsessive-Compulsive
Disorder – Phenomenology, Pathophysiology and Treatment, Pallanti S, Barns J,
Pittenger C, Eisen, J., Edited by Pittenger C. Oxford University Press, 2017
12.Handbook of Psychiatry and Behavioral Health, pp. 73 – 81, Malingering Fictitious
Disorder: The Assessment of Competence and (Capacity) and Forensic Aspects.,
Organs and Living Donars, and Trasplantation; The so-called “Biological
Testament”. Carocci Editori Roma, March 2020
13.Consultant to: Long version of the interdisciplinary evidence- and consensusbased
(S3) guideline “Attention-Deficit/Hyperactivity Disorder (ADHD) in children,
adolescents and adults” AWMF Registration No. 028-045. Published at AWMF
online. Association of Analytical Child and Adolescent Psychotherapists in Germany
(Vereinigung Analytischer Kinder- u. Jugendlichen-Psychotherapeuten in
Deutschland e. V., VAKJP)
14.Salerno L, Gaur S, Grassi G, Pallanti S. Neuromodulation in Attention-
Deficit/Hyperactivity Disorder: Toward a Precision Psychiatry Approach
Chapter in Bernardo Dell'Osso and Giorgio Di Lorenzo (Eds): Non Invasive
Brain Stimulation in Psychiatry and Clinical Neurosciences, 978-3-030-43355-
0, 479307_1_En, (9)
Books
1. Pallanti S., Vivere con le Voci, Vivere nel Silenzio, (Live with Voices, Live in Silence,
La nuova Italia Scientifica (1996)
2. Fossi G., Pallanti S., Manuale di Psichiatria (Manual of Psychiatry), Casa Editrice
Ambrosiana, Milano (1993)
3. Pallanti S., Koran L. M., Treatment of OCD Resistant Patients, Airon (2003)
4. Pallanti S., Bruscoli M., Le Emergenze Psichiatriche in Medicina, (Psychiatric
Emergency in Medicine) Lippincott /Williams and Wilkins, (2006) sold exclusively by
Innova Pharma SpA, Milano
5. Fossi G., Pallanti S., Psichiatria Elementare (Elementary Psychiatry), La Nuova Italia
Scientifica S.p.A. Roma. First edition 1993, 6th edition 2008
6. Pallanti, S. and Lauriello, J., Clinical Manual for Schizophrenia, Edited by B. Hales,
American Psychiatric Publishing. (2010)

Prof. Stefano Pallanti - CV 18 Agosto 2022

Prof. Stefano Pallanti - CV 18 Agosto 2022

Recommandé

Recommandé

Contenu connexe

Similaire à Prof. Stefano Pallanti - CV 18 Agosto 2022

Similaire à Prof. Stefano Pallanti - CV 18 Agosto 2022 (20)

Plus de Istituto di Neuroscienze del Prof. Stefano Pallanti

Plus de Istituto di Neuroscienze del Prof. Stefano Pallanti (16)

Dernier

Dernier (20)

Prof. Stefano Pallanti - CV 18 Agosto 2022